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ABSTRACT 
 
 
DNA Methylation in Lung Tissues of Mouse Offspring Exposed 
 
In Utero to Polycyclic Aromatic Hydrocarbons 
 
 
by 
 
 
Trevor J Fish, Master of Science 
 
Utah State University, 2015 
 
 
Major Professor: Dr. Abby D. Benninghoff 
Department: Animal, Dairy and Veterinary Sciences  
  
 
 Polycyclic aromatic hydrocarbons (PAHs) comprise an important class of 
environmental pollutants that are known to cause lung cancer in animals and are 
suspected lung carcinogens in humans. PAHs are also known to cause cancer in offspring 
when provided to a pregnant mouse. Moreover, evidence from cell-based studies points 
to PAHs as modulators of the epigenome, that is modifications to DNA structure that 
control the expression of genes. The objective of this thesis research was to determine the 
impact of transplacental exposure of PAHs on the epigenome of fetal and adult lung 
tissues in offspring exposed to either dibenzo[def,p]chrysene (DBC) or benzo[a]pyrene 
(BaP) throughout gestation and lactation. Lung tumor incidence in 45-week old mice 
initiated with BaP was 30%, much lower than that of the DBC-exposed offspring at 
100%. The spontaneous lung tumor rate was 9% in control offspring at 45-weeks. 
Promoter methylation for Cdkn2a, Rarb, Dapk1 and Mgmt genes was assessed by 
 
 
iv 
bisulfite sequencing. Laser capture microdissection was employed to assess the 
methylation of these selected tumor suppressor genes during the process of tumor 
progression. Analysis of methylation for the Cdkn2a promoter revealed a localized region 
of moderate methylation associated with CpG sites 27 to 30 in all samples evaluated. No 
differences in methylation were apparent for the other target genes. Genome-wide 
methylation of lung tumors in adult offspring was determined using the NimbleGen DNA 
Methylation array. The genome-wide assessment of CpG island promoter methylation 
revealed distinct patterns of methylation associated with normal and adenocarcinoma 
lung tissues. Furthermore, gene ontology analysis revealed differences in the biological 
functions represented by the methylated genes in normal lung tissues compared to tumor 
tissues. Altogether, the research presented here identified several new target genes of 
interest for future studies investigating the epigenetics of PAH-initiated lung cancer. This 
work also provided new knowledge that transplacental exposure to PAHs can lead to 
distinct DNA methylation profiles in lung tumors in adult offspring. 
(169 pages) 
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PUBLIC ABSTRACT 
 
 
DNA Methylation in Lung Tissues of Mouse Offspring Exposed 
 
In Utero to Polycyclic Aromatic Hydrocarbons 
 
 
by 
 
 
Trevor J Fish, Master of Science 
Utah State University, 2015 
 
 
Major Professor: Dr. Abby D. Benninghoff 
Department: Animal, Dairy and Veterinary Sciences  
 
 
 Polycyclic aromatic hydrocarbons (PAHs) comprise an important class of 
environmental pollutants that are known to cause lung cancer in animals and suspected 
lung carcinogens in humans. PAHs are also known to cause cancer in offspring when 
provided to a pregnant mouse. Some evidence from cell-based studies points to PAHs as 
modulators of the epigenome, that is modifications to DNA structure that control the 
expression of genes. Inappropriate changes to the epigenome and consequently 
expression of cancer-critical genes are often characteristic of cancer cells. The objective 
of this thesis research was to determine the impact of transplacental exposure to two 
model PAHs on the epigenome of fetal and adult lung tissues in offspring. Specifically, 
we measured patterns of methylation of DNA, a type of epigenetic mark, in different 
types of lung tissue to assess changes in the epigenome associated with development of 
lung cancer. Two strategies were employed: 1) a targeted approach using ultra-deep 
bisulfite sequencing to precisely measure the specific pattern of methylated sites in the 
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promoter regulatory region for several tumor suppressor genes, including Cdkn2a, Rarb, 
Dapk1 and Mgmt; and 2) a broad, genome-wide approach using a microarray covering all 
regulatory promoter regions in the entire mouse genome. Our first approach did not yield 
any marked differences in methylation patterns for any of the target genes for lung tissues 
obtained at birth or at various ages up to 45 weeks, nor according to the type of tissue 
(normal, pre-neoplastic, tumor). However, the genome-wide approach did yield specific 
patterns of methylation in lung tumors, including distinct profiles associated with lung 
tumor tissue from PAH-exposed animals that were substantially different from normal 
lung tissue in control animals. Altogether, the research presented here identified several 
new target genes of interest for future studies investigating the epigenetics of PAH-
initiated lung cancer. This work also provided new knowledge that exposure to PAHs can 
lead to distinct DNA methylation profiles in lung tumors in adult offspring. 
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INTRODUCTION 
 
 Statistics on Lung Cancer   
Lung cancer is the leading cause of cancer death worldwide and is the most 
common cancer in the world, with estimated deaths totaling 1,590,000 in 2012. New 
cases were estimated to be 1.8 million in 2012, 58% of which occurred in economically 
less-developed regions of the world (Fig. 1) (Ferlay, et al., 2013). For the United States, 
 
 
FIG. 1. Worldwide lung cancer incidence and mortality. (A) Estimated number of 
cases for the most common cancers worldwide in 2012. (B) Bars represent the 
estimated number of new lung cancer cases and the estimated number of lung cancer 
deaths as a percentage of all cancers (excluding non-melanoma skin cancers) for male 
or females in developed (dark blue) or developing (light blue) nations. Numbers above 
the bar represent the number of cases or deaths. (C) World map depicting incidence of 
lung cancer by nation for both males and females (values shown are the age-
standardized rate per 100,000 people). Source data were obtained from the 
GLOBOCAN 2012 database (Ferlay, et al., 2013). 
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an estimated 224,210 new cases of lung cancer were documented in 2014, a number that 
accounts for about 13% of all cancer diagnoses that year. The estimated new cases of 
lung cancer for both males and females rank second after prostate cancer for males and 
breast cancer for females. The rate of lung cancer incidence in men started to decline in 
the mid-1980s, whereas a decline was evident for women in the mid-2000s (American 
Cancer Society, 2015). Estimated deaths in 2014 due to lung cancer are higher than the 
combined total for prostate cancer, breast cancer, and colorectal cancer (Siegel et al., 
2014). Lung cancer is a deadly disease with a poor five-year survival rate of only 17%. In 
addition, roughly half of lung cancer patients die within one year of being diagnosed 
(Howlader N, 2015; Siegel, et al., 2014). 
 The two main types of lung cancer are small cell lung cancer (13% of cases) and 
non-small cell lung cancer (83%), with non-small cell lung cancer (NSCLC) being 
further classified within three main subtypes: adenocarcinoma, squamous-cell carcinoma 
and large-cell carcinoma (American Cancer Society, 2015). Adenocarcinoma is usually 
found in peripheral locations of the lung but also can be observed centrally in a main 
bronchus. Squamous-cell lung carcinoma tends to be found near the middle of the lungs, 
near a bronchus. Large-cell carcinoma can appear in any part of the lung. 
Adenocarcinoma is the predominant form of lung cancer diagnosed in never-
smokers, whereas smokers develop all major histological types of lung cancer 
(MacKinnon et al., 2010). The diagnosis and staging of lung cancer are often performed 
simultaneously, and some of the common tests and procedures used include physical 
exam, chest x-ray, CT scan, biopsy, sputum cytology and immunohistochemistry. 
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NSCLC progresses through several stages as it develops from simple abnormal cells to 
full adenocarcinoma of the lung. Briefly, in stage 0, also called carcinoma in situ, 
abnormal cells are found in the lining of airways. In stage I patients, the cancer is 
localized to the lungs but has not spread to any lymph nodes outside the lung. Stage II is 
typified by spread of the cancer to nearby lymph nodes. Stage III is subdivided into IIIA 
and IIIB depending upon the location of the tumor and the infiltrated lymph nodes. Stage 
IV is the most advanced stage of lung cancer in which cancer has spread to both lungs 
and metastasized to other organs, such as the brain, liver, adrenal glands, kidneys or bone 
(National Cancer Institute, 2015). Metastases to these critical organs account for the 
majority of lung cancer deaths (Nichols et al., 2012).  
 Lung cancer incidence and mortality vary with respect to race. The Centers for 
Disease Control and Prevention (CDC) reported that among men, black men had the 
highest rates for lung cancer incidence and mortality, followed by white men and then by 
men representing other ethnic groups. Conversely, white women had the highest 
incidence and mortality rates, followed by black women (Centers for Disease Control and 
Prevention, 2014). As with many cancers, risk of developing lung cancer increases with 
age. 
 Today, lung cancer risk typically is greater in men than in women, and the higher 
risk apparent for men has been attributed to smoking habits, environment and lifestyle 
choices (Freedman et al., 2008; Sun et al., 2007). The issue of gender in lung cancer risk 
has been debated since the early 1990s, at which time reports from case control studies 
showed higher odds ratio in women than men (Osann et al., 1993; Risch et al., 1993; 
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Zang and Wynder, 1996). Cohort studies consistently found higher lung cancer death 
rates in men than women, both in the presence (Thun et al., 2002) and absence (Thun et 
al., 2008; Thun et al., 2006) of smoking. However, this pattern did not appear to be 
consistent when considering newly diagnosed cases (Bach et al., 2003). Some researchers 
have hypothesized that, among smokers, women may have higher risk of developing lung 
cancer than men but lower risk of dying from the disease (Henschke and Miettinen, 2004; 
Henschke et al., 2006). Additionally, Wakelee, et al. (2007) documented that lung cancer 
incidence rates were higher in women than men among never-smokers. The accumulated 
evidence supports the notion that lung cancer risk is not consistent for men and women. 
Further research is needed to elucidate the gender differences in respect to lung cancer 
risk.  
 Lung cancer risk is also elevated among people with genetic susceptibility, such 
as the carriers of tumor protein 53 (TP53) germline sequence variations, often as a 
hereditary feature (Molina et al., 2008). The tumor suppressor gene TP53 plays a vital 
role in the process of apoptosis and is an important stress response molecule that is 
activated in response to diverse intrinsic and extrinsic signals (Rozan and El-Deiry, 
2007). In addition, there is a linear relationship between TP53 mutation risk and tobacco 
consumption, as mutations of this gene are less frequent in never-smokers than in those 
who smoke (Hernandez-Boussard and Hainaut, 1998; Le Calvez et al., 2005). Increased 
lung cancer risk is also associated with mutations in other genes, including epidermal 
growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and kirsten rat 
sarcoma viral oncogene homolog (KRAS) (Couraud et al., 2012; Pendharkar et al., 2013). 
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EGFR is responsible for a cascade of biological effects in normal cells and is often 
involved in cancer cell biology by activating tumorigenic processes, such as cell 
proliferation and angiogenesis (Schlessinger, 2002). ALK is a receptor tyrosine kinase 
and the EML4 (echinoderm microtubule–associated protein–like 4)-ALK fusion is the 
most common ALK rearrangement in NSCLC (Choi et al., 2008; Pendharkar, et al., 
2013). This receptor has gained clinical relevance and importance as a therapeutic target 
for NSCLC. KRAS is involved primarily in regulating cell division as part of the 
RAS/mitogen-activated protein kinase (MAPK) signaling pathway. KRAS mutations are 
found in 20-30% of NSCLC cases, predominately in adenocarcinomas (Couraud, et al., 
2012). Changes in these and other genes may make some lung cancers more likely to 
grow and metastasize.  
 Cigarette smoking is by far the most important risk factor for lung cancer. About 
90% of lung cancer cases have been attributed to this behavior, and risk of lung cancer 
increases with both quantity and duration of smoking (Centers for Disease Control and 
Prevention, 2014). Besides smoking cigarettes, several other environmental risk factors 
may increase the chance of developing lung cancer. Exposure to radon gas released from 
soil and building materials is estimated to be the second leading cause of lung cancer in 
Europe and North America (American Cancer Society, 2015). Other risk factors include 
environmental or occupational exposure to asbestos, silica, certain metals (cadmium, 
nickel, chromium, arsenic), radiation, air pollution, soot, tar and diesel exhaust 
(American Cancer Society, 2015; Centers for Disease Control and Prevention, 2014; 
Molina, et al., 2008; Siegel, et al., 2014). Never-smokers account for 10-15% of all lung 
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cancer cases, and these are typically associated with combination of genetic factors and 
exposure to other forms of air pollution (Thun, et al., 2008). Some researchers regard 
lung cancer in never-smokers as a different disease, which would then be ranked as the 
seventh leading cause of cancer death worldwide (Sun, et al., 2007; Wakelee, et al., 
2007).  
 
Polycyclic Aromatic Hydrocarbons   
Polycyclic Aromatic Hydrocarbons (PAHs) comprise a large class of structurally 
diverse organic molecules comprised of two or more fused aromatic rings (Fig. 2). PAHs 
are non-polar, lipophilic, organic compounds that do not contain any heteroatoms. Fully 
aromatic PAHs are generally planar with a molecular thickness of 3.7 Å (Harvey, 1991). 
 
 
 
FIG. 2. Chemical structures for example polycyclic aromatic hydrocarbons. 
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PAHs present in the environment usually originate from anthropogenic sources and are 
formed during incomplete combustion of organic matter. Shen et al. (2013) reported the 
major global atmospheric emissions of PAHs in 2007 to be residential/commercial 
biomass burning (60.5%), open-field biomass burning (agricultural waste burning, 
deforestation, and wildfire, 13.6%), and motor vehicles (12.8%). Natural events such as 
forest fires, natural oil seeps and volcanic activity also release PAHs into the atmosphere. 
Thermal decomposition of nearly any organic material may lead to the formation of 
PAHs. Other important anthropogenic sources of PAHs include cigarette smoke, 
industrial coke production, asphalt roads, coal tar, incineration, industrial power 
generation and hazardous waste sites (Luch, 2005). Benzo[a]pyrene (BaP) is one of the 
most common PAHs detected in the environment; annual production of BaP was 
estimated to range between 300 and 1,300 metric tons. An estimated 11,000 metric tons 
of all PAHs were released to the atmosphere on an annual basis (ATSDR, 1995). 
PAHs are widely distributed in human food as a result of contamination from air, 
soil and water, or as a byproduct of certain food preparation processes (e.g., frying, 
grilling, smoking or charbroiling fish or meat) (Phillips, 1999). Amounts of PAHs present 
in food are highly variable, but can be as high as parts per billion, depending on the food 
item and the way that it is prepared. For non-smokers, food is considered one of the main 
sources of human PAH exposure in the general public. The average total daily intake of 
PAHs by a member of the general population has been estimated to be 0.207 µg/day from 
air, 0.027 µg/day from water, and 0.16 to 1.6 µg/day from food (ATSDR, 1995). Tobacco 
smoke is one of the most important sources of PAH exposure indoors. Cigarettes contain 
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72 known human or animal carcinogens, including BaP at 13.5 ng per cigarette and the 
most abundant carcinogen, N’-nitrosonornicotine (NNN) at 70.5 ng per cigarette (Hecht, 
2011).  
More than two centuries ago, Percivall Pott (1775), a surgeon in St. Bartholo-
mew’s Hospital in London, England, described the occurrence of scrotal cancer in 
chimney sweeps and traced it to the contamination of the skin by soot, now known to be a 
major source of PAHs. Nearly 100 years later, Volkmann and Bell described several 
cases of scrotal skin tumors among workers in the German and Scottish paraffin industry 
(Bell, 1876; Volkmann, 1874). The first official acknowledgment that cancer of any 
cutaneous site could be caused by pitch, tar or tarry substances was made in an addendum 
to the Workmen’s Compensation Act of Great Britain in 1907, which stated that “scrotal 
epithelioma occurring in chimney sweeps and epitheliomattous cancer or ulceration of 
the skin occurring in the handling or use of pitch, tar or tarry compound” (Henry, 1947). 
Following these observations, researchers embarked on a series of systematic 
studies to address the potential for PAHs to cause cancer. Yamagiwa and Ichikawa 
(1918) were successful in achieving the production of malignant epithelial tumors by 
repetitive application of coal tar to the ear skin of rabbits. Further evidence that PAHs 
induce skin tumors in animals was obtained using ethereal extracts of soot (Passey and 
Carter-Braine, 1925). Around 1930, several researchers worked on the isolation and 
synthesis of hydrocarbons from coal tar (Cook et al., 1933; Hieger, 1930; Kennaway, 
1930; Kennaway and Hieger, 1930). During this time, BaP was first isolated and 
identified from coal tar (Cook, et al., 1933). Boyland and Levi (1935) discovered urinary 
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metabolites of small PAHs, such as anthracene and suggested that toxic hydrocarbons 
might either be converted into more active metabolites or be detoxified by conversion 
into other compounds.  
The two PAHs, dibenzo[def,p]chrysene (DBC) and BaP have been classified by 
the International Agency for Research on Cancer (IARC) as group 2A (probably 
carcinogenic to humans) and group 1 (carcinogenic to humans), respectively. The IARC 
reported that BaP produced tumors in all species tested (mouse, rat, hamster, guinea-pig, 
rabbit, duck, newt, monkey) for which data were reported following exposure by many 
different routes (oral, dermal, inhalation, intratracheal, intrabronchial, subcutaneous, 
intraperitoneal, intravenous) yielding many different tumor types (cancer of the liver, 
stomach, tongue, esophagus, lung, skin, breast, lymphoid and abdomen) (reviewed in 
(International Agency for Research on Cancer, 2012). DBC has been reported by the 
IARC to produce tumors in mice, rats, hamsters and fish with cancers of the skin, ovary, 
testicle, liver, stomach, lung, lymphoid and breast (reviewed in International Agency for 
Research on Cancer, 2010). With DBC as the most mutagenic and carcinogenic of all the 
PAHs (Bostrom et al., 2002) and BaP as the most extensively studied, these two PAHs 
are representative prototypes for environmental PAH toxins. 
  Women are unavoidably exposed to environmental pollutants during pregnancy. 
In non-occupational settings, most PAH exposures for non-smoking persons are 
associated with diet. The developing fetus and neonate are especially sensitive to 
chemical insults due to increased rates of cell division and underdeveloped detoxification 
and elimination pathways (Burdge and Lillycrop, 2010; Perera et al., 1999). Cancer risk 
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in adult life may be affected by transplacental exposure to environmental chemicals, 
resulting from greater relative DNA damage and a more rapid frequency of mutations 
during fetal development (Whyatt et al., 2001). Evidence suggests that many carcinogens 
are bioactive when administered transplacentally or perinatally and could be linked with 
childhood and adult cancers (Anderson, 2004; Anderson et al., 2000; Flower et al., 2004; 
Jensen et al., 2004; Lightfoot and Roman, 2004; Ma et al., 2002; Perera et al., 2005; 
Perera et al., 2004; Sandler et al., 1985; Sasco and Vainio, 1999; Tang et al., 2006; 
Whyatt et al., 2000; Zahm and Ward, 1998). Exposure during gestation and throughout 
breast feeding represents a significant portion of lifetime exposure to PAHs (Somogyi 
and Beck, 1993). 
 Studies using animal models have provided further evidence that transplacental 
exposure to environmental pollutants including PAHs, cigarette smoke, arsenic and 
benzene can induce carcinogenesis in offspring (Badham et al., 2010; Nicolov and 
Chernozemsky, 1979; Waalkes et al., 2007; Yu et al., 2006a). Scientists at Oregon State 
University demonstrated that DBC is a transplacental carcinogen in the mouse offspring 
from a cross of strains B6129F1/J dams and 129S1/SvlmJ sires (Yu, et al., 2006a). Mice 
treated with DBC had a high incidence of mortality due to aggressive T-cell 
lymphoblastic lymphoma as early as three months of age. Furthermore, mice surviving to 
ten months of age had a 100% incidence of lung adenomas (Yu, et al., 2006a). In 
subsequent studies, this group determined the critical role of CYP1B1 in DBC-initiated 
transplacental carcinogenesis in the development of the T-cell lymphoblastic lymphoma 
(Castro et al., 2008a). A cross fostering study demonstrated that the two to three day in 
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utero exposure to DBC resulted in much higher lymphoma-associated mortality than 
exposure to the residual DBC in the breast milk over three weeks of nursing, thus 
establishing that a brief exposure in utero is primarily responsible for the cancer response 
(Castro et al., 2008b). All the previously mentioned transplacental mouse models utilized 
a single dose of 15 mg/kg administered on gestation day (GD) 17. To more closely model 
episodic exposure throughout pregnancy, researchers dosed pregnant dams with four 
smaller amounts of DBC (3.75 mg/kg) on GD 5, 9, 13, and 17 (Shorey et al., 2012). This 
multiple dosing regimen lessened the lung tumor response in offspring at 10 months of 
age and eliminated mortality due to T-cell lymphoblastic lymphoma. These observations 
suggest that the target tissue response for transplacental PAH carcinogenesis in this 
mouse model is largely dependent upon the stage of fetal development upon exposure. 
Many chemical carcinogens exist in the environment as inert procarcinogens that 
require biological activation. Such is the case for PAHs, which are procarcinogens 
requiring metabolic activation by phase I cytochrome (CYP) P450 enzymes to generate 
their highly carcinogenic metabolites. CYP1A1 and CYP1B1 of the CYP1 family are the 
main enzymes to carry out metabolic activation of PAHs, while the other CYP enzymes 
in humans that play a lesser role in PAH metabolism, including CYP1A2, CYP2C9, 
CYP3A4 and CYP3A5 (Shimada and Fujii-Kuriyama, 2004). Metabolic activation of 
BaP is initiated by CYP1A1 oxidation to generate (+)- and (-)-BaP-7,8-oxides (Fig. 3). 
Then, epoxide hydrolase hydrolyses these oxides to produce (-)- and (+)-BaP-7,8-diol, 
which are further activated by CYP to highly reactive bay region epoxides, (+)-BaP-7,8-
diol-9,10-epoxide. The unstable epoxide intermediates may undergo conjugation with  
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glutathione (GSH) catalyzed by glutathione-s-transferases (GST) (Armsrong, 1997), 
nonenzymatic isomerization to phenols, or hydration catalyzed by epoxide hydrolase to 
form trans-dihydrodiols (Guenthner and Oesch, 1981). The GSH-conjugated metabolites 
are primarily excreted in the bile or transported to the kidney where they are converted to 
urinary excretable mercapturic acid conjugates (Hall and Grover, 1990). The phenol 
 
 
FIG. 3. Pathways for metabolic activation of benzo[a]pyrene. 
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conjugates may undergo further conjugation reactions with glucuronic acid or sulfate 
catalyzed by UDP-glucoronosyltransferase (UGT) and sulfotransferases (SULT), 
respectively. Both the sulfate and glucuronide conjugates are water soluble and easily 
excreted from the body (Burchell et al., 1997; Duffel, 1997). The highly reactive diol-
epoxide metabolites may undergo enzymatic conjugation with GSH or, alternatively, may 
covalently bind to cellular nucleophiles such as DNA, thereby forming DNA adducts 
(Hall and Grover, 1990). The stereo selectivity of PAH metabolism determines the 
configuration of the formed DNA adducts in each individual case. Depending upon the 
configuration of certain groups around the chiral center, there will theoretically be 
multiple conformations for any given DNA adduct (Harvey, 1991). BaP predominantly 
reacts with deoxyguanosine (dG) bases while DBC predominantly binds to 
deoxyadenosine (dA) residues to form DNA adducts (Mahadevan et al., 2007). However, 
not all DNA adduct formations have the same biological effect. The BaP-7, 8-diol-9, 10-
epoxide is a classical example which may form 16 different conformations in double 
stranded DNA. The (+)-trans-anti-BaPDE-N2-dG renders a high tumorigenicity (Conney, 
1982; Huberman et al., 1976; Newbold and Brookes, 1976; Phillips, 1983; Weinstein et 
al., 1976).  
Fjord region PAHs, such as DBC, are the most carcinogenic PAHs tested, thus far 
(Bostrom, et al., 2002; Higginbotham et al., 1993). Their potency is due, in part, to 
repulsive interactions between the two opposing hydrogen bonds present at the fjord 
region (Fig. 4). This repulsion renders the molecule out of plane such that the dihyrodiol-
epoxides can bind more extensively to DNA as compared to PAHs with only a bay region 
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FIG. 4. Pathways for metabolic activation of dibenzo[def,p]chrysene. 
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(e.g., BaP) (Geacintov et al., 2002; Wu et al., 2002). These structural effects of the fjord 
region conformation provide resistance to removal by DNA repair enzymes, leading to a 
higher incidence of tumor initiation (Buterin et al., 2000; Chakravarti et al., 2000). 
Expression of CYP1A1, CYP1A2 and CYP1B1 is induced by the presence of 
PAHs (Iwanari et al., 2002). Exposure to PAH procarcinogens increases the expression 
of the phase I enzyme that is responsible for their bioactivation. The induction of 
CYP1A1 expression is regulated by the intracellular aryl hydrocarbon receptor (AhR) to 
which PAHs chemically bind with high affinity. In the cytoplasm, AhR forms a complex 
with the 90 kDA heat shock protein, the X-associated protein 2 and co-chaperone protein. 
Following ligand binding, the AhR complex translocates into the nucleus, dissociates 
from the protein complex and binds to a nuclear protein called the AhR nuclear 
translocator (ARNT). Formation of the AhR-ARNT heterodimer converts the complex 
into its high affinity DNA binding form, which subsequently binds to its specific DNA 
recognition sites, the xenobiotic responsive elements (XREs), located upstream of the 
CYP1A1 gene. The binding of XRE results in an increase in chromatin and nucleosome 
disruption, an increase in promoter accessibility and an increase in the transcription of the 
CYP1A1 gene (Denison et al., 2002; Whitlock, 1999). 
Expression of phase I enzymes appears to play a role in the site of cancer 
development as demonstrated by their tissue specific expression patterns (Choudhary et 
al., 2003; Choudhary et al., 2005; McKinnon et al., 1991; Saarikoski et al., 1998). 
CYP1A1 is primarily expressed in extrahepatic tissues such as the lung (Nelson et al., 
1996). The CYP1B1 gene is highly expressed in many human organs including brain, 
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endometrium, placenta, fetal adrenal glands, lung, kidney, and lymphocytes (Hakkola et 
al., 1997; Sutter et al., 1994), although its expression in the liver is rather low. CYP1B1 
has been shown to activate BaP to its ultimate carcinogen metabolite at rates higher than 
CYP1A2 but lower than CYP1A1 (Kim et al., 1998). On the other hand, CYP1A1 and 
CYP1B1 appear to differ in their stereo-selective activation of DBC. CYP1B1 has been 
shown to form higher portions of the highly carcinogenic metabolite of DBC, as 
compared to CYP1A1 (Luch et al., 1998). 
 
Epigenetics and Lung Cancer 
The term epigenetics refers to specific patterns of chromatin structure and DNA 
modifications that remain constant through the rounds of cell division, but that do not 
involve changes to the DNA sequence. The epigenome is another layer of cellular 
information that controls, registers or signals altered chromosome and gene activity 
(Bird, 2007). Genes can become inactivated or permanently silenced by at least three 
pathways: 1) a gene can become mutated and lose its functionality, 2) a gene can become 
completely lost and thus not be available to perform its function and 3) a gene that has 
not been lost or mutated can be switched off through changes to its epigenetic code. 
Different combinations of pathways participate and cooperate with each other to cause 
either a gain of function or loss of function in critical regulatory genes (Baylin and Jones, 
2007). Genetic and epigenetic abnormalities can cause heritable disruptions to 
homeostatic pathways by two different mechanisms. Either the activation of an oncogene 
can occur resulting in a gain of function or tumor suppressor genes can be inactivated 
resulting in a loss of function (Hanahan and Weinberg, 2000; Herman and Baylin, 2003; 
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Jones and Baylin, 2002). These epigenetic changes can involve histone modifications, 
chromatin remodeling and methylation of cytosine in CpG sites within the promoter 
regions of genes. 
Histone modifications and chromatin remodeling are two interrelated processes 
that are regulated by post translational modifications of the nucleosome. The base unit of 
packaged DNA is called a nucleosome, which consists of 146 base pairs (bp) of DNA 
wrapped around an octamer of four core histone proteins (Luger et al., 1997). Histone 
proteins are an essential part of DNA packaging and chromosome structure. The N-
terminus amino acid tail of the histone protein protrudes away from the nucleosome 
which provides multiple sites for post translational modifications, including acetylation, 
methylation, ubiquitination and phosphorylation, that establish the histone code 
(reviewed in Delage and Dashwood, 2008). These epigenetic modifications regulate gene 
expression through the remodeling of the chromatin state. For example, methylation of 
particular residues on histone tails is key modification for regulating chromatin 
packaging and gene expression. In addition, acetylation of specific sites of the histone 
protein aid in the regulation of chromatin folding and transcriptional activation. 
Transcriptionally active regions of the genome reside in euchromatin, a decondensed 
chromatin state, whereas inactive regions reside in heterochromatin defined as highly 
compacted chromatin state. Due to the variety of epigenetic modifications, chromatin is a 
highly dynamic structure, prone to remodeling and restructuring as it receives input from 
upstream signaling pathways. The histone code works in concert with the DNA 
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methylation code to ensure an efficient regulation of chromatin structure and genes 
transcription (Delage and Dashwood, 2008). 
 CpG methylation can contribute to tumorigenesis via one of at least three 
mechanisms. These include global hypomethylation of the genome, focal 
hypermethylation of the proximal promoter region of tumor suppressor genes and 
transversions, in which meCpG is converted to TpG (Baylin and Jones, 2007). Three 
different types of DNA methyltransferases (DNMTs) are responsible for the methylation 
of DNA. DNMT1 is responsible for the maintenance methylation or the upkeep of the 
methylation code during cell replication. DNMT3a and 3b are responsible for the de novo 
methylation, that is, the initial pattern of methylation established during early 
development.  
The misregulation of genes controlling cell proliferation, cell cycle, DNA repair, 
inflammation, growth suppressor evasion, angiogenesis and cell metabolism can 
contribute to the development of tumorigenesis (Hanahan and Weinberg, 2011). Lung 
cancer involves an accumulation of genetic and epigenetic events in the cell (Dumitrescu, 
2012). Alterations of the epigenome have been associated with many cancers, in which a 
general pattern of DNA global hypomethylation and promoter hypermethylation have 
been observed. Although mutations in tumor suppressor genes and oncogenes are 
important for tumorigenesis, epigenetic modifications that also arise in response to DNA 
damage have a crucial role in cellular selection, leading to a growth advantage for the 
tumor cells at the expense of the host (Timp and Feinberg, 2013). Epigenetic alterations 
are, in fact, more frequent than somatic mutations in lung cancer (Brzezianska et al., 
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2013). Epigenetic variation in progenitor cells together with genetic lesions drives tumor 
progression. This early role for epigenetic alterations in cancer is in addition to epigenetic 
alterations that can substitute for genetic variation later in tumor progression. 
Epigenetically disrupted tumor suppressor genes in progenitor cells might be crucial 
targets for cancer risk assessment (Feinberg et al., 2006). Promoter methylation of 
specific tumor suppressor genes, along with the overall number of hypermethylated 
genes, increased with neoplastic progression from hyperplasia to adenocarcinoma (Chung 
et al., 2011; Licchesi et al., 2008).  
There have been numerous studies examining the functions of gene inactivation 
by promoter hypermethylation with respect to impacting tumorigenesis. Cyclin-
dependent kinase inhibitor 2a (Cdkn2a, also known as p16INK4a) was the first tumor 
suppressor gene found inactivated in lung cancer predominantly through aberrant gene 
promoter hypermethylation (Merlo, et al., 1995). Cdkn2a inhibits the cyclin-dependent 
kinases 4 and 6, which bind cyclin D1 and phosphorylate the retinoblastoma tumor 
suppressor gene (Lukas et al., 1995; Weinberg, 1995). Since the identification of Cdkn2a 
inactivation by promoter hypermethylation, epigenetic silencing has been associated with 
numerous other genes in lung cancer (Belinsky, 2004; Tsou et al., 2002). Methylation of 
the death-associated protein kinase (Dapk1) and retinoic acid receptor β (Rarb) genes 
were detected in approximately half of alveolar hyperplasia induced mouse lungs 
chronically exposed to 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) (Pulling, 
et al., 2004; Vuillemenot, et al., 2004). Loss of function for these two genes could 
significantly affect cellular apoptosis and normal cell differentiation control. O6-
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methylguanine-DNA methyltransferase (Mgmt) is a DNA repair enzyme that protects 
cells from the carcinogenic effects of alkylating agents by removing alkyl adducts from 
the O6 position of guanine. The predominant mechanism for Mgmt gene inactivation is 
hypermethylation within its promoter region that leads to transcriptional silencing in 27–
47% of lung adenocarcinomas (Esteller, et al., 1999; Furonaka, et al., 2005). The 
important functions of these genes and others inactivated through promoter 
hypermethylation supports a role for their involvement in the initiation and progression of 
lung carcinogenesis.  
 Several in vitro studies have shown that treatment of human cells with BaP or the 
carcinogenic metabolite benzo[a]pyrene-diolepoxide (BPDE) results in altered histone 
modification (Sadikovic et al., 2008), gene-specific DNA hypo-and hypermethylation 
(Damiani et al., 2008; Sadikovic and Rodenhiser, 2006) and altered expression of key 
genes involved in cancer cell transformation (Damiani, et al., 2008). Damiani, et al. 
(2008) functionally linked BPDE-induced changes in DNA methylation in transformed 
human bronchial epithelial cells from smokers with lung cancer to increased expression 
of DNMT1 (but not DNMTs 3a or 3b) and de novo methylation of a number of tumor 
suppressor genes, including E-cadherin, H-cadherin, protocadherin-10, Rassf2a and 
Pax5α among others. These early studies provide initial evidence that PAHs, specifically 
BaP, are capable of epigenome modification. However, it is not known whether in vivo 
exposure to PAHs disrupts patterns of gene promoter methylation. Moreover, it is also 
unknown whether transplacental exposure to PAHs alters the fetal/neonatal epigenome, 
specifically. 
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 Table 1 shows the methylation prevalence of four specific tumor suppressor genes 
known to be hypermethylated in human lung cancer and some mouse chemical cancer  
models. These four genes have diverse functions in carcinogenesis and were the focus of 
a major portion of the present study. Methylation prevalence is the ratio of the number of 
occurrences for detected methylation in the population studied. 
 
Project Objectives and Hypothesis 
The objective of this project was to determine the impact of transplacental exposure 
of PAHs on the neonatal and adult offspring epigenome in the mouse lung. We 
hypothesized that transplacental exposure to PAHs alters DNA methylation in the 
promoter region of key tumor suppressor genes leading to increased risk of lung cancer in 
the adult. The specific objectives were as follows: 
1. Determine the impact of transplacental exposure to DBC and BaP on methylation of 
the promoter regions of the Cdkn2a, Rarb, Dapk1 and Mgmt genes in neonate 
mouse lung. Determine the impact of transplacental exposure to DBC and BaP on 
genome-wide methylation of the lung tumors in the adult offspring mice.  2. Assess the timing of tumor suppressor gene silencing resulting from gestational 
PAH exposure by measuring gene promoter methylation in adult mice (aged 15 to 
45 weeks) as preneoplastic lesions develop into lung adenocarcinomas in the adults. 	
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MATERIALS AND METHODS 
 
Chemicals   
DBC and BaP were purchased from Sigma-Aldrich (St. Louis, MO; CAS No. 
191-30-0, CAS No. 50-32-8). Buffered 10% neutral formalin was purchased from VWR 
(Houston, TX). Optimal Cutting Temperature (OCT) Compound was obtained from 
Sakura Finetek (Torrence, CA). Arcturus® HistoGene® staining solution was purchased 
from Applied Biosystems (Foster City, CA). All other chemicals used were of reagent 
grade and purchased from general laboratory suppliers.  
 
Animals   
The Utah State University Institutional Animal Care and Use Committee 
approved all procedures for the handling and treatment of mice used in this study 
(Protocol #1442). Animals were housed in the USTAR BioInnovations Center’s 
Vivarium at Utah State University. All mice were maintained on a 12:12 hour dark:light 
cycle, and water was provided ad libitum. Eight week old B6129SF1/J females and 
129S1/SvImJ males were obtained from the Jackson Laboratory (Bar Harbor, ME) and 
bred to obtain a backcross strain that is sensitive to DBC and BaP as transplacental 
carcinogens (Castro, et al., 2008a; Yu, et al., 2006a). Moreover, B6129SF1/J mice  
possess an AhR-responsive allele, meaning that these mice are prone to carcinogenesis 
induced by PAHs via induction of Cyp1b1 and/or Cyp1a1 (Yu, et al., 2006a).  
Furthermore, the mouse Cyp1b1 has the highest activity toward conversion of DBC to the 
carcinogenic fjord region diol-epoxide (Castro et al., 2008c; Luch, et al., 1998). Dams 
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were fed AIN93G (Harlan-Teklad, Madison, WI) during pregnancy and lactation. 
Weaned offspring were fed AIN93G until three months of age, and were then fed 
AIN93M diet (Harlan-Teklad, Madison, WI) ad libitum until euthanasia. 
 
Experiment Design   
B6129SF1/J dams and 129S1/SvImJ sires were bred and day one of gestation was 
determined by the detection of the vaginal plug. On gestation days 5, 9, 13 and 17, 
pregnant mice were dosed by body weight with vehicle (5 ml/kg/day corn oil), 3.75 
mg/kg/day DBC (total dose 15 mg/kg) or 12.5 mg/kg/day BaP (total dose 50 mg/kg). Any 
mice exhibiting signs of morbidity, pain or distress during the study were humanely 
euthanized with an overdose of CO2 and necropsied.  
For the sham treatment group (group 1), 11 females were bred to 5 males to 
generate 93 pups. For the DBC group (group 2), 13 dams were bred to 7 males to 
generate 89 pups. Because BaP is a less potent carcinogen compared to DBC, we 
generated more animals for group 3 using 15 dams and 8 males to produce 131 offspring. 
Four litters from each group were used to obtain lung tissue from neonate offspring at 
day one of age. From these neonates, lung, liver, thymus and heart were collected and 
immediately frozen in liquid nitrogen and stored at -80°C. The tissues from all pups 
within each litter were combined to provide sufficient tissue for analysis, resulting in n = 
4 for each experimental group. 
At ages 15, 25, 35 and 45 weeks, six mice from group 1 and 2 and ten mice from 
group 3 were randomly selected to be euthanized to obtain tissues samples throughout the 
progression of lung tumor development, including normal tissue, preneoplastic lesions 
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(atypical adenomatous hyperplasia [AAH]) and lung adenocarcinomas. Example images 
depicting these tissue types in mouse lung are shown in Fig. 5. Lung tissues were 
collected and embedded in OCT for later processing and use in laser capture micro-
dissection (LCM). At 45 weeks, all remaining offspring from all experimental groups 
were humanely euthanized by CO2 asphyxiation and necropsied. Lung tumors present on 
the lungs of these 45 week-old mice were identified, counted and the diameter was 
measured by digital caliper. Half the lung was placed in the 10% neutral buffered 
formalin, while the other half was frozen in liquid nitrogen and stored at -80°C. At each 
necropsy, body weights and spleen, kidney, liver, and heart weights were recorded; these 
organs were stored in 10% buffered neutral formalin. 
 
Lung Tissue Collection and Processing  
Lung tissues designated for analysis by LCM were processed in two halves, each 
of which was placed into a 12×12×20 mm embedding mold, covered with OCT 
compound and then submerged in chilled isopentane until solidification of OCT, 
 
 
FIG. 5. Representative microscopy images of mouse lung tissues collected for laser 
capture microdissection. (A) normal lung tissue, (B) atypical adenomatous 
hyperplasia, and (C) adenocarcinoma. 
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according to the supplier’s protocol. Frozen tissue blocks were stored at -80°C until 
further processing.  
Sectioning of the tissue blocks was completed using the Leica CM1950 cryostat 
(Leica Biosystems, Buffalo Grove, IL). Tissue sections were cut with 8 µm thickness and 
placed onto Arcturus® polyethylene naphthalate (PEN) membrane slides (Applied 
Biosystems, Foster City, CA). The slides were immediately placed into a microslide box 
on dry ice. Next, slides were immersed in 75% ethanol (v/v) for 30 sec followed by 
distilled water for 30 sec and then removed. Next, 100 µl of Arcturus® HistoGene® 
staining solution was applied to each slide for 20 sec. Then, slides were sequentially 
immersed for 30 sec each in distilled water, 75% (v/v) ethanol, 95% (v/v) ethanol and 
100% ethanol and then finally 5 min in xylene. The slides were dried in a ventilated hood 
for an additional five minutes and then stored at -80°C until LCM.  
Slide sections were examined by a board certified Veterinary Pathologist at the 
Utah Veterinary Diagnostics Laboratory to localize tissue types to be collected by LCM. 
For this analysis, only tissues from mice in group 1 (sham) and group 2 (DBC-initiated) 
were used. Tissue types collected for LCM included normal adjacent lung, AAH and lung 
adenocarcinomas for mice aged 25 to 45 weeks initiated with DBC in utero (group 2). 
Only normal lung tissue was collected for mice in group 1 at all ages and for mice in 
group 2 at age 15 weeks as there was no evidence of AAH in DBC-initiated offspring at 
this age. Tissues were collected from four of the six mice euthanized at each time point, 
as not all tissue types were evident in every mouse (i.e., AAH was evident in only four of 
the six mice collected at 25 weeks).  
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LCM collection was performed on Arcturus® Veritas™ laser capture micro 
dissection instrument at the University of Utah Cell Imaging core facility. LCM was 
performed using an infrared (IR) laser, which captured the cells of interest directly onto 
Arcturus® CapSure® Macro LCM caps (Applied Biosystems, Foster City, CA). Caps with 
tissues were then snapped onto 0.5 ml microcentrifuge tubes, and then DNA from the 
captured tissues was extracted using the Arcturus® PicoPure® DNA Extraction Kit 
(Applied Biosystems, Foster City, CA) according to the supplied protocol with no 
deviation. 
Frozen lung tissues from neonate offspring were pooled by litter (n = 4 litters per 
group), and DNA and total RNA were isolated from these tissues using TRI Reagent® 
(Sigma-Aldrich, St. Louis, MO) according to the supplier’s protocol.  
 
Roche 454 Sequencing 
DNA collected from LCM-captured lung tissues from group one and two mice 
and from neonate lungs was utilized for bisulfite deep sequencing. All DNA samples 
were bisulfite-converted using the EZ DNA Methylation Kit™ (Zymo Research, Irvine, 
CA). Then, the bisulfite-converted DNA was subject to a genomic pre-amplification step 
using Fluidigm’s Specific Target Amplification (Preamplification) protocol (Fluidigm, 
South San Francisco, CA). Table 2 shows the primer sequences utilized for 
preamplification and library preparation, and Fig. 6 shows the location of primer sets 
with respect to predicted CpG islands for each target gene. Genomic sequence 
information was obtained from the Ensembl Genome Browser (Flicek et al., 2012), and 
primer sequences were designed using MethPrimer software (Li and Dahiya, 2002). The 
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FIG. 6. Location of primer sequences with respect to predicted CpG islands for 
selected genes. Red arrow pairs indicate regions targeted for generating amplicons for 
ultra-deep bisulfite sequencing. The scale indicates position with respect to the 
transcript start site at exon 1 (first black bar). CpG islands (light blue) were predicted 
using EMBOSS Cpgplot (Li et al., 2015).  
TABLE 2 
Primers Used for Bisulfite Sequencing  
Gene Primer (5’ to 3’) Positiona  CpG sites 
Cdkn2a    
For [CS1]-GATGGATTTGGAGTAAGGGAAA -366 41 
Rev [CS2]-CCCAAAAACRCCCAAAAA -86  
Dapk1    
For [CS1]-GTGTGGGGGTTTTTTAGTTTAGATT 340 22 
Rev [CS2]-CTTCCTAATACCTACCCAATTCCTC 635  
Mgmt    
For [CS1]-GTTTTAGGTTTGGAAGAAGAGGTTT -280 20 
Rev [CS2]-CACAAATTTTAAATACCTAAACACCAA 15  
Rarb    
For [CS1]-GGTTTGGTTAGGAATAGGAGAGTAGA -351 17 
Rev [CS2]-AACAACCCTACAAAAACCTTCAAC -165  
Note: For, forward primer; Rev, reverse primer; CS1, common sequence tag 1 (5’-
acactgacgacatggttctaca-3’); CS2, common sequence tag 2 (5’-tacggtagcagagacttggtct-3’).  
a Position number specifies the bp location of the genomic primer’s 5’ end in relation to the 
first bp of the first exon of the gene.  
 
 
 
29 
genome target specific primers were designed to contain a 22 bp Fluidigm forward or 
reverse common sequence tag (CS1 or CS2) at the 5’ end.   
The Fluidigm 48.48 Access Array system was used for library preparation of the 
samples and our four target genes following the manufacturers supplied protocols. 
Briefly, bisulfite-modified preamplified DNA was combined with master mix from the 
FastStart High Fidelity PCR System, dNTPack (Roche, Bradford, CT) following 
manufacturer’s protocol and then loaded into the primed 48.48 access array plate. Each 
plate was run on the BioMark system (Fluidigm, South San Francisco, CA), which 
utilizes Fluidigm’s integrated fluidic circuits for automating the PCR reactions in 
nanoliter volumes. Three 48.48 access array plates were utilized to amplify all samples, 
and each gene was duplicated eight times across both plates with one exception.  Mgmt 
was duplicated 16 times on each plate in order to more closely balance the ultimate yield 
of sequence reads from each amplicon, as amplification of Mgmt was roughly half as 
efficient as the other genes. Products from the Access Array were subjected to 
electrophoresis on a 2% agarose gel for visual conformation of adequate amplification 
and appropriate amplicon size. Gel bands corresponding to each amplicon were excised, 
and DNA was extracted using Qiagen’s QIAquick® Gel Extraction Kit (Qiagen, 
Valencia, CA). A secondary amplification, using a standard thermocycler, was performed 
utilizing primers that contained the 25 bp Roche 454 A and B adaptor sequences (adapter 
A, CGTATCGCCTCCCTCGCGCCATCAG on the forward primer and adapter B, 
CTATGCGCCTTGCCAGCCCGCTCAG on the reverse primer), the 10 bp multiplex 
identifier (MID) and the CS1 or CS2 tags, respectively. This second round of PCR used 
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1µl of the PCR product from the first round and 2 µM primer in master mix from the 
FastStart High Fidelity PCR System, dNTPack (Roche, Bradford, CT) and the following 
cycling parameters: 95°C for 10 min for 1 cycle, 95°C for 15 sec, annealing temperature 
of 60°C for 30 sec, and 72°C for 1 min for 15 cycles and the final stage of 72°C for 3 min 
for 1 cycle. At the conclusion of the second round of PCR, the amplicons contain all the 
necessary elements for 454 sequencing.  
DNA samples were then subjected to electrophoresis on a 2% agarose gel for 
visual conformation of adequate amplification and appropriate amplicon size. The DNA 
bands were excised and DNA was extracted using Qiagen’s QIAquick® Gel Extraction 
Kit. Finally, the fully processed DNA was sent to the Center for Integrated BioSystems at 
Utah State University to be sequenced on the Roche 454 Sequencer (Roche, Bradford, 
CT). Briefly, amplicon libraries were subjected to emulsion PCR to produce DNA-coated 
beads, loaded onto a 70×75 PicoTiterPlate, and sequenced using the FLX Titanium DNA 
sequencing Kit according to the manufacturer’s protocol.  
 
NimbleGen DNA Methylation Array   
Genome-wide DNA methylation analysis of offspring lung tissues was performed 
using the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq 
Promoter Array (Roche NimbleGen Inc., Basel, Switzerland). Tissue types analyzed 
included normal lung tissue from sham-initiated offspring and normal adjacent lung 
tissues and lung tumors from 45 week-old offspring initiated with DBC or BaP in utero.  
High-quality genomic DNA was extracted from lung tissue using the DNeasy Blood & 
Tissue Kit (Qiagen, Valencia, CA). One microgram of genomic DNA was restriction-
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digested with Mse I restriction enzyme (New England BioLabs, Ipswich, MA) to generate 
200 to 1000 bp fragments. Samples were subjected to heat denaturation for 20 min at 
65°C in order to stop the reaction. DNA samples were then purified using QIAquick PCR 
Purification Kit (Qiagen, Valencia, CA), and DNA concentration was determined using a 
NanoDrop spectrophotometer (Thermo Fisher Scientific). Verification of fragment size, 
using 200 ng of sample was performed by gel electrophoresis (2% agarose gel). An 
aliquot of 10 to 15 ng was reserved after quantification for use as control (input DNA). 
The remainder was immunoprecipitated using the Methylated-DNA IP Kit (Zymo 
Research, Irvine, CA; Cat. No. D5101). Because the quantity of MeDIP DNA obtained 
was insufficient for processing the genome-wide arrays, a whole-genome amplification 
step was required. Whole-genome amplification was performed utilizing a series of two 
kits with a starting amount of 10 ng for both input and MeDIP DNA as per 
manufacturer's instructions. The first kit used was GenomePlex® Complete Whole 
Genome Amplification (WGA) Kit (Sigma-Aldrich Company, St. Louis, MO), or WGA2 
kit. The second was GenomePlex® WGA Reamplification Kit (Sigma-Aldrich Company, 
St. Louis, MO) or WGA3 kit. Following processing of samples through this two-kit 
procedure, the WGA-amplified DNA was then purified using QIAquick PCR Purification 
Kit (Qiagen, Valencia, CA), and 5 µg of DNA per sample were provided to NimbleGen 
(Roche NimbleGen Inc, Basel, Switzerland) for array hybridization and preliminary data 
processing. 
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Data Analysis 
Statistical analysis of lung tumor multiplicity was performed using one-way 
ANOVA with Bonferroni’s test for multiple comparisons (GraphPad Prism vers. 6, 
LaJolla, CA). Lung tumor incidence in 45-week old offspring exposed in utero to BaP 
was analyzed using Fisher’s exact test (GraphPad Prism).  
Sequencing data generated by Roche 454 were processed using Amplicon Variant 
Analyzer (Roche, Bradford, CT). Sequences were separated by sample according to their 
barcode sequences, and barcodes were trimmed off. The resulting sequences were then 
aligned to reference sequences for each amplicon and the primer sequences were 
trimmed. BioEdit Sequence Alignment Editor was then used to prepare and edit the 
individual alignment files for each sample/amplicon (Hall, 1999).  
The processed data were subjected to analysis of CpG methylation frequency 
using the Bisulfite Sequencing DNA Methylation Analysis (BISMA) program (Rohde et 
al., 2010). First, data files (limited to 400 sequence reads per file) uploaded to BISMA 
were automatically subjected to a multiple sequence alignment and quality control 
analysis on the following parameters: defined quality and specificity criteria of sequence 
identity, percentage of insertions/deletions, conversion rate and percentage of unresolved 
annotations. Sequences that did not pass these quality criteria were automatically 
removed from subsequent analysis. BISMA analysis generated output for each sequence 
analyzed, including the calculated average methylation at each CpG position and the 
average methylation for the entire sequence. Also, the program generated an aligned 
sequence map depicting methylation status for each CpG site for each included sequence. 
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Data received from NimbleGen’s genome-wide DNA methylation analysis 
consisted of processed data files as well as the raw data files for all samples submitted. 
Raw data files contained signal intensity data from the scanned images of each array 
obtained using NimbleScan. Peak data files (processed data files) were generated from 
the raw signal intensity data by Nimblegen. Briefly, for each array feature, a scaled log2 
ratio was calculated as the ratio of the input signals for the experimental and control 
samples co-hybridized to the array. The log2 ratio was computed and scaled to center the 
ratio data around zero. Scaling was performed by subtracting the bi-weight mean for the 
log2 ratio values for all features on the array from each log2 ratio value. From the scaled 
log2 ratio data, a fixed-length window (750 bp) was placed around each consecutive 
probe, and the one-sided Kolmogorov-Smirnov (KS) test was applied to determine 
whether the probes are drawn from a significantly more positive distribution of intensity 
log-ratios than those in the rest of the array. The resulting score for each probe is the 
−log10 p-value from the windowed KS test around that probe. Using NimbleScan, peak 
data files were generated from the p-value data files. NimbleScan detects peaks by 
searching for at least two probes above a −log10 p-value minimum cutoff of 2. Peaks 
within 500 bp of each other were merged. Finally, the “peak score” was calculated as the 
average −log10 p-values from probes within that peak. Two sets of processed data files 
with these calculated peak scores were generated by Nimblegen. One set contained data 
for all peak scores near a given transcript, while the second set included data for only the 
peak score nearest the transcription start site of a given gene. 
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 Gene lists for functional ontology analysis were generated by selecting features 
with peak score > 2 (indicative of methylated DNA) in all three samples from the 
treatment group of interest and by excluding all features that were not methylated (peak 
score <2) in at least 2 of the 3 samples from the comparison treatment group(s). Using 
these criteria, for example, genes listed as methylated in sham samples were consistently 
methylated in only the sham tissues and mostly not methylated in other tissues. Gene 
ontology analysis was performed using the AgriGO singular enrichment analysis (SEA) 
tool (Du et al., 2010) against the mouse gene ontology database (Mouse Genome 
Informatics) with the following parameters: Fisher test with FDR under dependency 
correction and significance level of P<0.05 and the minimum number of mapping entries 
set at five genes. The gene ontology type performed was a generic GO slim (Gene 
Ontology Consortium).  
  
 
 
35 
RESULTS 
 
Lung Tumorigenesis in 45 Week-Old Offspring 
Lung tumor incidence was 29.5% in 45 week-old offspring initiated in utero with 
BaP, much lower than the 100% incidence rate observed for the more potent carcinogen 
DBC (Fig. 7A). The spontaneous lung tumor rate in sham-initiated offspring mice at 45 
weeks of age was 8.9%. A similar pattern was observed for lung tumor multiplicity, 
calculated as the number of lung tumors per tumor-bearing animal (Fig. 7). Sham-
initiated mice that developed lung cancer spontaneously did so with a very low 
multiplicity (one tumor per animal), and multiplicity in BaP-initiated offspring was 
similarly low with only one to two tumors per animal. Alternatively, DBC-initiated 
 
 
 
 
FIG. 7. Lung tumorigenesis in offspring exposed to PAHs in utero. (A) Values for 
tumor incidence are indicated by the height of the bar for each group, and tumor 
multiplicity is indicated by bar shading. ***, P < 0.001 for tumor multiplicity 
compared to Sham and BaP treatment groups as determined by one-way ANOVA with 
Bonferroni’s post hoc test for multiple comparisons. (B) Values shown are the percent 
of male and female offspring initiated in utero with BaP with lung tumors at 45 weeks 
of age. **, P = 0.0018 as determined by Fisher’s exact test. 
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offspring had a significantly higher average tumor multiplicity of six tumors per tumor-
bearing animal (P < 0.0001). Interestingly, lung tumor incidence in 45 week-old 
offspring exposed in utero to BaP was significantly lower in females (12%) compared to 
their male counterparts (50%) (P = 0.0018) (Fig. 7B). Although statistical analysis 
suggested that lung tumor incidence was different between the sexes in mice initiated 
with BaP, this result should be interpreted with some caution given the relatively small 
number of mice that developed tumors within this treatment group. There was no 
apparent difference observed in lung tumor incidence in DBC-initiated mice, as all 
animals exposed to this carcinogen developed lung cancer, as has been repeatedly 
observed in this model (Castro, et al., 2008b; Risch, et al., 1993; Yu, et al., 2006a).  
 
Amplicon Bisulfite Sequencing Analysis  
DNA promoter methylation patterns were examined using bisulfite sequencing of 
CpG sites at single base pair resolution across four genes from DNA collected via LCM. 
The average percent methylation values corresponding to the CpG site sequenced are 
provided in Tables 3-6, with the data organized according to the sample type, animal age 
and the amplicon sequenced. Unsupervised bi-directional hierarchical clustering was 
performed using average methylation data for each comparison group to identify 
distinctions in methylation profiles according to age (neonate, 15, 25, 35 or 45 weeks), 
type of carcinogen exposure (Sham, DBC or BaP) or tissue type (normal, AAH or 
tumor). Clustering was also performed using methylation data for each individual mouse 
to assess variation in methylation profiles within and across age, carcinogen exposure and 
tissue-type groupings.
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TABLE 3 
Average Methylation per CpG Site for the Cdkn2a Promoter Region Sequenced by Roche 454 a 
    
CpG Site Number b 
Carcinogen Age 
Tissue  
type 
Number 
reads c 4 7 14 27 36 43 54 59 66 70 73 82 88 92 98 106 125 129 134 138 140 145 147 150 163 165 175 179 184 188 195 200 209 211 221 229 235 245 247 249 251 
Sham Neonate Normal 11 0.0 0.0 0.0 0.0 0.0 4.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 16.7 22.9 22.9 12.5 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Sham 15wk Normal 793 0.2 0.0 2.2 0.3 0.2 0.1 0.6 0.2 0.9 0.6 0.7 0.6 0.3 0.5 1.5 0.2 0.1 0.2 0.6 0.2 0.3 0.1 0.2 0.2 0.2 1.4 31.4 43.3 42.1 22.2 0.2 0.1 0.0 0.1 1.0 0.1 0.0 0.2 1.3 0.4 0.3 
Sham 25wk Normal 1042 0.6 0.4 3.6 1.8 0.9 1.2 0.3 6.9 0.5 1.0 0.3 0.4 0.3 0.2 0.7 0.4 0.3 0.7 0.4 0.9 0.0 0.2 0.2 0.4 1.3 0.7 15.6 24.0 14.2 11.8 0.2 0.2 0.4 0.4 0.2 0.1 0.5 0.3 0.5 0.2 0.0 
Sham 35wk Normal 915 0.2 0.2 0.2 0.8 0.6 1.0 0.1 0.6 0.5 0.3 1.0 0.0 0.2 0.7 1.7 0.6 0.2 0.8 0.5 0.5 1.2 0.2 0.2 0.3 0.7 0.8 18.4 26.6 23.2 11.4 0.5 0.8 1.1 0.5 0.2 0.2 0.7 0.1 0.3 1.3 0.2 
Sham 45wk Normal 654 0.0 0.4 0.6 1.3 0.0 0.5 0.2 0.5 0.3 0.3 0.4 0.4 0.3 0.2 0.1 0.1 0.7 0.0 0.1 3.7 0.6 0.2 0.5 0.0 0.1 0.2 55.1 60.5 61.2 30.5 1.2 0.2 0.5 0.4 0.2 0.3 0.0 0.4 0.1 0.2 0.0 
DBC Neonate Normal 9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 28.6 28.6 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
BaP Neonate Normal 21 0.0 0.0 0.0 3.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 20.7 40.7 40.7 12.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
DBC 15wk Normal 149 0.5 0.0 0.0 0.5 0.5 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 2.8 0.5 0.0 0.3 0.3 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 15.9 21.6 21.6 7.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.3 3.5 0.3 0.3 
DBC 25wk Normal 409 0.9 1.1 0.3 0.9 0.2 0.9 0.5 0.5 0.6 0.5 0.2 0.5 0.3 0.6 0.8 0.4 0.0 0.0 1.0 0.9 0.8 0.8 0.6 1.2 1.3 0.4 12.3 18.0 20.3 5.1 0.9 0.2 1.2 1.0 0.2 0.2 0.2 0.0 0.5 1.0 0.3 
DBC 25wk AAH 324 0.1 0.8 0.0 0.0 0.3 0.4 0.0 2.0 1.1 0.0 0.6 0.0 0.0 1.4 0.8 0.0 0.0 0.1 3.6 0.1 1.5 0.0 1.1 0.1 0.5 0.0 10.6 9.9 11.4 6.6 0.0 0.0 0.9 0.3 0.0 0.0 0.1 0.0 0.1 0.1 0.0 
DBC 25wk Tumor 168 0.8 0.0 1.2 1.1 0.0 0.0 0.0 1.3 0.0 0.0 2.4 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.4 0.0 0.0 0.4 0.0 11.2 29.9 35.8 4.8 0.4 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.4 0.0 
DBC 35wk Normal 459 0.0 0.2 0.0 0.2 0.3 1.1 0.0 0.6 0.2 0.6 0.9 0.3 0.0 0.5 2.4 0.0 0.3 0.8 0.2 0.2 0.3 0.5 2.0 3.0 1.8 0.6 11.4 22.6 23.5 13.3 0.8 0.2 0.2 0.2 0.3 0.2 0.2 0.5 0.3 0.6 0.2 
DBC 35wk AAH 654 0.1 0.0 0.7 0.4 0.0 1.0 0.2 0.2 0.4 0.3 0.2 0.2 0.3 0.4 0.4 0.2 0.4 0.3 0.6 0.5 0.3 0.2 0.4 0.0 0.4 0.3 31.9 17.4 14.5 10.1 0.7 0.3 0.1 0.6 0.3 0.0 0.5 0.6 0.0 0.6 0.7 
DBC 35wk Tumor 830 0.6 0.2 0.0 0.8 0.3 0.9 0.4 0.7 0.7 0.3 0.0 0.3 0.2 0.3 0.5 0.1 2.5 0.1 0.3 0.8 0.3 0.2 0.3 0.0 0.2 1.0 22.1 40.2 37.6 20.5 1.0 0.6 1.4 0.3 0.2 0.0 1.8 0.1 0.5 0.6 0.4 
DBC 45wk Normal 1303 0.2 0.3 1.0 0.9 0.2 1.1 0.7 0.4 0.4 0.1 0.3 0.3 0.4 0.2 0.5 0.4 0.9 0.4 0.3 0.7 0.1 0.6 0.1 0.5 0.1 2.2 15.7 28.7 27.8 9.2 0.6 0.7 0.4 0.6 0.3 0.2 0.3 0.8 0.7 0.3 0.4 
DBC 45wk AAH 392 0.7 0.3 0.6 0.3 0.5 0.0 0.5 0.6 0.3 0.3 0.3 0.6 2.4 0.0 9.7 0.3 0.3 0.3 1.0 0.6 0.0 0.0 0.3 0.5 0.0 0.0 22.7 37.4 32.5 18.0 0.6 1.6 0.3 0.6 0.0 0.3 1.5 1.2 0.3 0.0 8.0 
DBC 45wk Tumor 852 0.2 0.1 0.2 0.2 0.5 0.1 0.3 4.0 0.7 0.3 0.3 0.2 0.1 0.2 0.9 0.3 0.8 0.2 0.0 0.2 0.0 8.8 0.1 0.2 1.4 0.0 17.4 30.1 29.1 16.1 1.0 0.1 0.2 0.0 0.4 0.0 0.7 1.2 0.5 0.2 0.6 
Color key   
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 
 
a Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table. 
b CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.  
c Number shown is the total number of reads associated with each amplicon for each sample. 
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 TABLE 4 
 Average Methylation per CpG Site for the Dapk1 Promoter Region Sequenced by Roche 454 a 
    CpG Site Number b 
Carcinogen Age 
Tissue 
type 
Number 
reads c 11 13 26 28 38 44 66 84 120 141 149 154 157 171 176 178 184 209 246 252 261 267 
Sham Neonate Normal 
                       Sham 15w Normal 545 0.8 1.9 0.0 0.8 0.1 0.1 0.4 1.7 0.3 0.5 0.2 0.1 0.2 0.5 1.5 0.4 0.6 0.3 0.0 0.5 0.1 0.5 
Sham 25w Normal 1023 0.1 0.5 0.4 0.4 0.3 1.2 1.2 0.8 1.3 0.1 1.2 0.6 1.2 0.7 0.7 0.3 1.1 0.8 0.2 0.0 0.1 0.6 
Sham  35w Normal 246 1.5 1.4 0.0 0.5 0.6 0.7 0.0 0.0 0.9 0.8 0.0 2.0 3.3 0.9 1.3 0.9 1.1 0.0 0.0 0.0 0.7 0.5 
Sham 45w Normal 133 0.6 2.2 2.6 0.0 0.0 0.6 0.6 0.0 3.3 0.5 2.6 1.2 1.3 0.0 1.4 0.0 0.0 0.7 0.0 0.0 0.7 0.0 
DBC  Neonate Normal d 
                      BaP  Neonate Normal d 
                      DBC 15w Normal 55 0.0 2.1 0.0 0.0 0.0 0.0 1.4 0.0 0.0 0.7 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 
DBC 25w Normal 94 5.3 3.6 0.0 0.0 0.0 0.0 0.0 0.9 1.1 0.0 0.0 0.0 3.0 1.1 0.0 0.0 0.0 0.0 0.0 1.0 1.1 0.0 
DBC 25w AAH 41 4.2 7.0 0.0 0.0 0.0 0.0 0.0 4.2 2.8 4.2 0.0 0.0 0.0 0.0 0.0 0.0 10.7 4.2 4.2 4.2 0.0 4.2 
DBC 25w Tumor 33 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 4.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
DBC 35w Normal 132 9.4 8.9 0.4 0.0 0.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 1.6 1.1 0.0 0.0 1.1 0.4 0.0 
DBC 35w AAH 72 4.4 4.9 0.0 0.0 0.0 0.0 0.0 2.6 8.4 2.8 0.0 1.4 1.7 2.6 2.9 9.3 0.0 3.0 0.0 0.0 0.9 0.0 
DBC 35w Tumor 178 1.5 1.3 0.0 0.0 0.7 0.0 0.0 0.0 1.6 0.4 2.2 1.7 0.4 1.2 0.0 0.0 0.7 2.8 0.0 0.0 1.3 2.0 
DBC 45w Normal 699 0.2 0.3 0.6 0.6 0.5 1.2 0.0 2.2 1.7 0.6 0.2 0.4 1.2 0.6 0.8 0.2 0.7 2.0 0.2 0.2 0.5 1.1 
DBC 45w AAH 229 4.9 4.9 4.6 5.0 0.0 4.6 4.5 0.0 7.4 4.3 4.6 4.0 4.3 4.6 4.6 5.2 4.9 4.9 1.0 1.0 1.4 0.3 
DBC 45w Tumor 269 0.9 2.5 0.0 0.2 0.1 0.0 0.0 0.3 0.0 0.3 0.3 0.0 0.0 0.0 0.0 0.0 1.6 0.1 0.0 0.0 0.3 0.3 
Color key   
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 
 
a Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table. 
b CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.  
c Number shown is the total number of reads associated with each amplicon for each sample. 
d Sequencing of this amplicon failed for the samples indicated. 
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 TABLE 5 
 Average Methylation per CpG Site for the Mgmt Promoter Region Sequenced by Roche 454 a 
    CpG Site Number b 
Carcinogen Age Tissue type 
Number 
reads c 13 37 48 62 77 88 106 111 113 124 137 181 187 206 218 229 235 237 243 248 
Sham Neonate Normal 23 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 5.0 0.0 0.0 0.0 3.6 0.0 0.0 0.0 
Sham 15w Normal 950 0.0 1.7 4.6 1.2 0.0 1.0 1.2 0.2 0.4 0.8 1.3 0.2 1.8 0.3 1.1 1.3 1.9 0.9 1.2 1.3 
Sham 25w Normal 1239 1.4 0.8 1.1 0.8 1.7 1.2 1.1 1.0 1.4 1.1 0.6 1.3 0.8 0.9 0.5 0.4 1.2 1.3 1.5 1.1 
Sham  35w Normal 959 0.2 1.2 0.7 1.2 3.0 0.3 0.7 0.6 0.4 0.6 0.3 1.0 0.7 0.2 0.7 0.7 0.8 1.8 0.7 0.8 
Sham 45w Normal 996 0.3 0.5 0.1 0.1 0.8 1.3 0.4 0.7 0.8 0.9 0.4 0.8 0.8 0.5 0.7 0.7 1.0 1.2 0.7 0.5 
DBC Neonate Normal 72 1.1 0.0 1.1 0.0 0.0 0.0 1.1 0.0 1.9 1.1 4.2 0.0 0.0 1.3 0.0 0.7 1.1 0.0 0.0 0.0 
BaP Neonate Normal 61 0.0 0.0 0.0 2.9 0.0 1.1 1.1 1.1 1.1 1.1 2.3 2.3 1.1 1.1 1.1 2.5 1.1 2.7 5.3 2.3 
DBC 15w Normal 439 0.0 0.0 0.0 0.3 0.4 0.2 0.0 0.6 0.2 0.0 0.0 0.4 0.2 0.8 0.5 0.5 0.2 0.3 0.8 0.7 
DBC 25w Normal 1014 0.7 0.5 0.6 0.7 2.9 0.5 0.4 0.9 0.7 0.6 0.4 1.6 1.5 0.8 2.1 1.2 1.5 1.7 1.5 1.4 
DBC 25w AAH 621 3.5 4.6 3.4 5.0 8.0 3.8 5.1 4.1 5.5 2.9 3.0 6.9 5.6 3.7 6.1 3.7 6.5 6.8 6.7 5.8 
DBC 25w Tumor 446 2.9 3.5 4.9 4.6 6.8 3.9 4.4 4.6 4.2 3.7 0.4 4.6 4.3 1.5 1.8 4.3 4.9 4.4 4.2 5.5 
DBC 35w Normal 932 2.9 2.4 1.9 3.5 8.3 2.0 5.5 1.9 3.1 2.0 0.4 2.7 1.7 0.5 1.7 8.7 1.8 2.0 1.7 1.7 
DBC 35w AAH 827 1.7 4.3 2.3 6.2 4.8 2.3 2.2 1.8 4.8 3.1 1.1 0.8 0.7 0.9 0.8 0.6 0.6 1.2 2.0 2.0 
DBC 35w Tumor 1223 0.3 3.9 3.0 0.8 4.8 3.6 3.5 3.2 5.8 1.8 1.6 3.8 2.3 1.3 1.2 1.8 1.6 0.9 3.2 3.4 
DBC 45w Normal 1183 0.2 0.4 0.3 0.6 0.7 0.9 1.5 1.0 2.2 1.1 0.3 0.8 0.7 0.8 0.5 0.4 0.5 1.2 1.3 0.8 
DBC 45w AAH 1115 0.2 1.8 1.0 0.4 1.2 0.5 8.8 0.5 0.3 0.2 0.3 0.3 0.5 0.3 0.6 0.4 0.1 5.4 0.3 0.4 
DBC 45w Tumor 1180 11.1 12.2 11.8 10.6 3.3 7.8 7.3 7.4 10.7 2.6 6.1 4.0 3.4 0.3 2.3 2.3 1.4 3.3 9.4 8.5 
Color key   
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 
 
a Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table. 
b CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.  
c Number shown is the total number of reads associated with each amplicon for each sample. 
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 TABLE 6 
 Average Methylation per CpG Site for the Rarb Promoter Region Sequenced by Roche 454 a 
    CpG Site Number b 
Carcinogen Age Tissue type 
Number 
reads c 16 27 48 52 63 70 76 84 96 116 124 136 138 140 148 150 156 
Sham Neonate Normal 146 0.5 1.3 0.0 0.0 2.0 0.7 0.0 0.0 0.5 0.0 0.0 0.7 0.5 0.0 0.0 1.3 0.0 
Sham 15w Normal 1520 4.2 3.4 0.8 0.8 0.9 0.6 1.8 0.7 0.5 0.4 0.1 0.0 0.2 0.7 0.7 0.7 0.3 
Sham 25w Normal 1557 0.5 0.7 0.2 0.7 1.2 0.9 0.6 1.7 0.7 0.6 0.4 1.0 0.7 0.9 0.2 0.2 0.6 
Sham  35w Normal 1507 7.0 8.1 0.5 1.1 2.6 0.6 1.0 0.5 0.7 1.4 0.5 0.9 0.6 0.9 0.4 0.5 0.5 
Sham 45w Normal 1510 9.6 5.3 0.6 0.9 1.5 0.5 0.7 0.6 0.6 0.6 1.1 0.5 0.3 0.6 0.7 0.3 0.9 
DBC Neonate Normal 206 0.0 0.9 0.7 0.0 0.8 0.0 0.7 1.4 0.7 0.7 0.3 0.3 1.4 0.5 0.3 0.5 0.5 
BaP Neonate Normal 269 0.2 1.1 0.0 0.0 0.7 0.2 0.0 1.1 1.2 0.9 0.9 2.0 2.1 0.0 0.0 0.2 0.7 
DBC 15w Normal 1079 3.5 2.9 1.0 1.3 1.8 0.8 0.5 1.1 0.4 0.4 0.3 0.4 0.4 0.4 0.6 0.3 0.3 
DBC 25w Normal 1427 5.1 8.4 1.4 2.1 2.5 1.6 1.2 1.4 1.5 0.5 0.7 0.9 0.7 0.7 1.0 0.4 0.8 
DBC 25w AAH 1434 10.1 7.9 3.9 4.7 4.6 3.5 2.1 2.3 3.4 4.7 1.6 1.7 0.8 1.3 1.5 0.3 1.0 
DBC 25w Tumor 1124 4.1 2.1 0.3 5.8 8.7 1.0 5.3 1.0 0.8 0.9 0.4 0.4 1.0 2.8 0.7 0.4 1.0 
DBC 35w Normal 1473 7.5 5.0 1.1 1.1 1.5 1.0 0.6 0.6 0.6 1.1 0.3 1.0 0.8 0.4 0.9 0.3 1.6 
DBC 35w AAH 1079 7.3 8.9 0.9 2.9 4.0 2.6 1.6 0.1 1.1 0.6 0.6 1.9 1.5 1.3 1.0 1.3 0.7 
DBC 35w Tumor 1531 14.3 1.1 1.3 2.9 3.2 1.5 1.2 0.4 0.7 1.1 0.6 0.4 0.2 0.5 0.8 0.5 0.4 
DBC 45w Normal 1456 4.6 0.2 0.6 1.8 1.6 0.7 1.1 0.5 0.5 0.8 0.9 0.4 0.4 0.4 0.6 0.8 0.5 
DBC 45w AAH 1463 1.5 2.8 0.9 0.3 2.2 0.6 1.1 1.2 0.3 0.6 0.2 0.4 0.4 1.1 1.1 0.1 0.1 
DBC 45w Tumor 1486 8.0 0.4 0.9 2.6 1.3 2.0 1.4 0.2 0.9 0.6 0.9 1.7 0.4 0.7 0.7 0.8 0.2 
Color key   
0.0 10.0 20.0 30.0 40.0 50.0 60.0 70.0 80.0 90.0 100.0 
 
a Each heat map cell indicates the percentage of CpG sites positive for methylation. Blue corresponds to low methylation and red to high methylation according to color key shown below the table. 
b CpG site number specifies the specific base pair location of the CpG site in relation to the first base pair of the first exon.  
c Number shown is the total number of reads associated with each amplicon for each sample. 
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 Overall, methylation of CpG sites in the amplicon sequenced for Cdkn2a was 
minimal (<10%), with one region from sites 27 to 30 showing a moderate methylation 
frequency (15 to 60 %) (Fig. 8). Results of hierarchical clustering according to animal 
group showed that sham mice had a similar methylation profile, with the exception of 25 
week-old sham mice, which grouped more closely with DBC-initiated offspring (Fig. 
8A). When considering each individual mouse methylation pattern, no distinct clusters 
were evident, likely due to the broad pattern of overall very low methylation evident 
across all samples for most CpG sites (Fig. 8B).  
 Analysis of methylation for Dapk1 (Fig. 9) revealed that the region sequenced is 
consistently unmethylated in lung tissues from all ages of offspring, with no discernible 
differences among sham, DBC- or BaP-initiated mice. Cluster analysis did not reveal any 
pattern in methylation for age, carcinogen treatment or tissue type for average 
methylation data (Fig. 9A). Small groupings of two to three animals by tissue type, such 
as 35 week DBC-initiated mice were observed in the bi-directional hierarchical clustering 
of the individual mouse methylation profiles (Fig. 9B). Results for methylation analyses 
of the Mgmt and Rarb amplicons was similar to that for Dapk1 in that the frequency of 
methylation was very low for all the CpG sites examined, and no clear patterns emerged 
from the unsupervised clustering according to offspring age, carcinogen exposure or the 
type of lung tissue (Fig. 10 and 11). 
FIG. 8. Methylation profile for region of Cdkn2a gene promoter by 454 deep bisulfite 
sequencing. Each heat map cell indicates the percentage of CpG sites positive for 
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar 
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average 
methylation of groups for each time point (n = 4 mice per group). Green bars indicate 
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with 
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bi-
directional hierarchical clustering of each sampled mouse individually with mice labeled 
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time 
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate. 
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FIG. 9. Methylation profile for region of Dapk1 gene promoter by 454 deep bisulfite 
sequencing. Each heat map cell indicates the percentage of CpG sites positive for 
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar 
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average 
methylation of groups for each time point (n = 4 mice per group). Green bars indicate 
sample groupings for lung tissues from sham-initiated offspring and offspring initiated 
with DBC at multiple time points. (B) Bi-directional hierarchical clustering of each 
sampled mouse individually with mice labeled A-D for each time, tissue type. Colored 
boxes indicate grouping per animal for each time point and tissue type. N, normal; H, 
hyperplasia; T, tumor; Neo, neonate. 
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 FIG. 10. Methylation profile for region of Mgmt gene promoter by 454 deep bisulfite 
sequencing. Each heat map cell indicates the percentage of CpG sites positive for 
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar 
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average 
methylation of groups for each time point (n = 4 mice per group). Green bars indicate 
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with 
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bi-
directional hierarchical clustering of each sampled mouse individually with mice labeled 
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time 
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate. 
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 FIG. 11. Methylation profile for region of Rarb gene promoter by 454 deep bisulfite 
sequencing. Each heat map cell indicates the percentage of CpG sites positive for 
methylation. Heat map shading indicates percent methylation for each CpG site (scale bar 
blue to red shown at bottom). (A) Bi-directional hierarchical clustering of the average 
methylation of groups for each time point (n = 4 mice per group). Green bars indicate 
sample groupings for lung tissues from sham-initiated offspring, neonates initiated with 
DBC and BaP and offspring initiated with DBC at multiple time points. (B) Bi-
directional hierarchical clustering of each sampled mouse individually with mice labeled 
A-D for each time, tissue type. Colored boxes indicate grouping per animal for each time 
point and tissue type. N, normal; H, hyperplasia; T, tumor; Neo, neonate. 
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Genome-Wide Methylation Analysis 
The impact of transplacental exposure to DBC and BaP on DNA methylation of 
lung tumors and normal adjacent lung tissue in the adult offspring mice was assessed 
utilizing NimbleGen’s genome-wide DNA methylation promoter array. The processed 
array data obtained from NimbleGen are provided as calculated peak scores for all 
methylation peaks detected on the array (Appendix A) (Fish, 2015a) and calculated peak 
scores for peaks nearest to transcription start site (Appendix B) (Fish, 2015b). Given the 
small sample size of three in individuals per tissue type, the large number of observations 
and the limited range of values for peak scores, we did not expect to detect significant 
differences among the treatment groups using standard statistical analysis for 
microarrays. Thus, we employed a gene ontology analytical approach to determine 
whether differences were evident among the biological pathways represented by 
differentially methylated genes for the various lung tissue types examined, including: 
normal sham, normal adjacent in DBC-initiated offspring (AdjDBC), tumor in DBC-
initiated offspring (TumDBC), normal adjacent in BaP-initiated offspring (AdjBaP), and 
tumor in BaP-initiated offspring (TumBaP). A summary table of peak scores for all genes 
identified as methylated in any sample is provided in Table C.1 of Apendix C (Fish, 
2015c), which was generated using the processed data for nearest peak scores. This 
summary table was then used to generate gene lists with unique terms (e.g., methylated in 
sham tissues but not in AdjDBC or TumDBC tissues) for further analysis. Gene lists for 
all comparisons of interest are provided in Table E.2 of Appendix D (Fish, 2015d). 
 
 
47 
Functional gene ontology (GO) analysis of differentially methylated genes for 
adjacent and tumor tissue of lungs from DBC- or BaP-initiated mice and from sham-  
initiated mice revealed differences in the GO terms for biological processes associated 
with each group. Each of the Venn diagrams (Fig. 12) depicts the number of differentially 
methylated genes identified for each sample type used in the functional gene ontology 
 
 
FIG. 12. Venn diagrams depicting segregation of differentially methylated genes 
among lung tissue types, as well as the number of genes similarly methylated among 
groups (overlapping regions). (A) Venn diagram depicts the number of genes identified 
as methylated for sham normal lung tissue, normal adjacent (AdjDBC) and tumor tissue 
(TumDBC) from DBC-initiated offspring. (B) Venn diagram depicts the number of 
genes identified as methylated for sham normal lung tissue, normal adjacent 
(AdjBaP)and tumor tissue (TumBaP) from BaP-initiated offspring. (C) Venn diagram 
depicts the number of genes identified as methylated for sham normal lung tissue and 
tumor tissues from both BaP- and DBC-initiated offspring. Coloring of Venn diagrams 
corresponds to colors assigned to tissue types in Tables 7-9. 
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analysis, as well as the number of genes similarly methylated among groups (overlapping 
regions). This GO analysis, based on the differentially methylated gene lists of a given 
comparison, reports what functions are associated with genes methylated in a select tissue 
sample. For example, the analysis identifies GO terms associated with genes methylated 
in sham tissues, but not methylated in tumor DBC or adjacent DBC tissues. Results of 
gene ontology analysis are presented here for biological process terms only; see Tables 
E.1-E.3 (Appendix E) for complete results of ontology analysis, including GO terms and 
FDR values for biological process, cellular compartment and molecular function. 
By populating the gene list for ontology analysis with genes that were uniquely 
methylated in specific sample types (e.g., normal tissue from sham-initiated mice) or 
groupings of samples (e.g., genes methylated in tumors from BaP- and DBC-initiated 
mice), we were able to identify biological functions associated with promoter 
hypermethylation specific to a tissue type. Table 7 and Fig. 13 depict functional gene 
ontology analysis of differently methylated genes for adjacent and tumor tissues of lungs 
from DBC-initiated mice and from normal lung tissue of sham-initiated mice. A total of 
44 categories are represented by the comparison of the differentially methylated gene 
lists. Genes in the methylated Sham list are represented in 40 of the 44 enriched GO 
terms, while the methylated tumor DBC gene list is composed of 35 enriched GO terms. 
Interestingly, there are only four enriched GO terms associated with the methylated genes 
in the normal adjacent DBC tissue samples. The strength of enrichment is indicated by 
the FDR-adjusted p-value. While 31 terms appear in both Sham and TumDBC enriched 
GO term lists, it is important to note that genes that made up the comparison lists for 
 FIG. 13. Biological processes associated with genes differentially methylated in lung 
tumors from both DBC- and BaP-initiated offspring. Gene ontology map for GO terms 
representing hypermethylated gene promoters unique to lung tumor tissues from DBC- 
and BaP-initiated offspring (not sham). Gene ontology analysis was performed using the 
AgriGO singular enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO) 
against the mouse gene ontology database (Mouse Genome Informatics). Significantly 
enriched GO terms (Generic GO Slim) were determined using the Fisher test with an 
FDR-corrected significance level of P<0.05 (Yekutieli multi-test adjustment method) and 
the minimum number of mapping entries set at 5 genes.  
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performing the GO analysis were entirely unique. Furthermore, this analysis does not 
discern the regulatory function of the genes in the lists, but can facilitate the exploration 
of biological meaning in higher order pathways and the inter-relationships between terms. 
Within this comparison (Sham vs. AdjDBC and TumDBC), methylated genes were over- 
represented in biological function categories unique to normal lung tissue of sham-
initiated mice include cell cycle (FDR = 1.50E-02), regulation of gene expression (FDR = 
5.00E-04), transcription (FDR = 5.80E-03) and protein modification process (FDR = 
6.60E-04), among others. Genes methylated in tumor tissue from DBC-initiated mice 
were over-represented in biological function categories cell communication (FDR = 
2.10E-02) and growth (FDR = 3.50E-02).  
Fig. 14 and Table 8 show the results of functional analysis of differently 
methylated genes for adjacent and tumor tissues of lungs from BaP-initiated mice and 
from normal lung tissue of sham-initiated mice. A total of 40 enriched GO terms are 
represented, of which 36 are associated with the genes methylated in tumor BaP samples, 
20 are associated with genes methylated in normal adjacent BaP tissue, and only 6 GO 
terms are over-represented from genes methylated in normal lung tissue of sham-initiated 
mice. The higher number of enriched categories for tumor BaP suggests that the 
methylation profile associated with tumor BaP is more functionally diverse than that of 
either normal adjacent BaP or Sham profiles. Tumor tissue from BaP-initiated mice 
yielded a methylation profile enriched for genes associated with cell-cell signaling (FDR 
= 1.10E-02), cellular developmental process (FDR = 4.0E-03) and translation (FDR = 
54 
 
 
 
FIG. 14. Biological processes associated with genes differentially methylated in 
normal lung tissue from sham-initiated offspring. Gene Ontology map for GO terms 
representing hypermethylated gene promoters unique to sham tissues (not methylated in 
lung tumors from DBC- or BaP-initiated offspring). Gene ontology analysis was 
performed using the AgriGO singular enrichment analysis (SEA) tool 
(http://bioinfo.cau.edu.cn/agriGO) against the mouse gene ontology database (Mouse 
Genome Informatics). Significantly enriched GO terms (Generic GO Slim) were 
determined using the Fisher test with an FDR-corrected significance level of P<0.05 
(Yekutieli multi-test adjustment method) and the minimum number of mapping entries 
set at 5 genes. 
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8.0E-03) GO terms, among other processes unique to the list. Both normal lung tissue of 
sham-initiated mice and tumor tissue of lungs from BaP-initiated mice yielded 
methylation profiles enriched for genes associated with the cell proliferation GO term 
(FDR = 3.90E-02, 2.0E-02, respectively).  
Fig. 15 and Table 9 depict functional analysis of differently methylated genes for 
tumor tissues obtained from lungs of DBC- and/or BaP-initiated mice and from normal 
lung tissue of sham-initiated mice. The enriched GO terms represented by all four 
comparison groups methylated gene lists total 42, with normal lung tissue from sham-
initiated mice containing the most functionally diverse list of genes. In addition to Table 
5, Fig. 13-15 provide graphical representations of the enriched GO terms for each of the 
different tissue types compared. Normal lung tissue of sham-initiated mice yielded the 
most functionally diverse methylation profile enriched for genes in sham (not TumDBC 
or TumBaP) (Fig. 14) associated with embryonic development (FDR = 3.50E-02), cell 
proliferation (FDR = 1.80E-02), cell differentiation (FDR = 3.60E-03), gene expression 
(FDR = 1.30E-03) and transcription (FDR = 2.10E-03) among the total 37 biological 
processes represented in the list. The least functionally diverse or most uniform gene list 
within this comparison was of tumor tissue from DBC-initiated mice. The TumDBC (not 
sham or TumBaP) methylation gene list was associated with only five enriched pathways 
(Fig. 15). The functional diversity between the lists of tumor BaP and tumor DBC plus 
BaP does not seem to differ much when based on the number of enriched pathways 
represented by each list, 20 and 22, respectively. However, there is diversity between the 
two lists as only ten of the 22 enriched GO terms for tumor DBC plus BaP are similarly 
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FIG. 15. Biological processes associated with genes differentially methylated in lung 
tumor for either DBC- or BaP initiated offspring. (A) GO map for GO terms representing 
hypermethylated gene promoters unique to tumor tissues from DBC-initiated mice (not 
methylated in sham lung tissue or lung tumors from BaP-initiated offspring). (B) GO map 
for GO terms representing hypermethylated gene promoters unique to tumor tissues from 
BaP-initiated mice (not methylated in sham lung tissue or lung tumors from DBC-
initiated offspring). Gene ontology analysis was performed using the AgriGO singular 
enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO) against the mouse 
gene ontology database (Mouse Genome Informatics). Significantly enriched GO terms 
(Generic GO Slim) were determined using the Fisher test with an FDR-corrected 
significance level of P<0.05 (Yekutieli multi-test adjustment method) and the minimum 
number of mapping entries set at 5 genes.  
<1e$09'
<0.05'
FDR$p$value$ Rela*onship$
Methylated in TumDBC  
(not sham or TumBaP) 
Methylated in TumBaP (not sham or TumDBC) B A 
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enriched within the tumor BaP gene list. Again, it is important to note that genes that 
made up the comparison lists for performing the GO analysis were entirely unique. GO 
terms enriched by hypermethylated gene promoters for lung tumor tissues from DBC- 
and BaP-initiated offspring (not sham) (Fig. 13) were nucleobase, nucleoside, nucleotide 
and nucleic acid metabolic process (FDR = 5.20E-03), regulation of gene expression 
(FDR = 2.50E-03), gene expression (FDR = 2.80E-03) and transcription (FDR = 1.40E-
03), among the twelve pathways not similarly enriched for the BaP gene list. Tumor 
tissue from BaP-initiated mice yielded a methylation profile enriched for genes in 
TumBaP (not sham or TumDBC) (Fig. 15) associated with cell differentiation (FDR = 
2.0E-02), cell communication (FDR = 5.60E-03), transport (FDR = 2.10E-03) and 
homeostatic process (FDR = 2.0E-02) among other biological processes. See Fig. F.1-
F.10 in Appendix F (Fish, 2015e) for GO maps of other comparisons among tissue types 
using gene lists provided in Appendix D (Fish, 2015d).  In summary, this gene ontology 
analysis showed that transplacental PAH exposure altered biological pathways associated 
with the regulation and control of many critical processes involved in lung tumorigenesis. 
Ten genes were selected for further post-hoc inspection based on observations 
from the DNA methylation array and their relevance to tumorigenesis, including Bcl2l11, 
Bmp1, Fgfr1op, Hoxb1, Pdcd4, Casp7, Il11, Pten, Maea, and Tpd52l1. For each of these 
genes, the peak score data were aligned with sequence information to inspect patterns of 
methylation across all sample types using SignalMap software. Interestingly, for some 
genes selected for post-hoc inspection, the NimbleGen-predicted CpG island did not 
overlap with the identified region(s) of high methylation according to the array data.  In 
 
 
 
64 
addition, EMBOSS Cpgplot (Li, et al., 2015) was used as an independent prediction tool 
to confirm CpG islands for the selected genes.  The Cpgplot-predicted CpG islands 
coincided with the NimbleGen-predicted CpG island for each gene. Furthermore, for 
several genes the Cpgplot-prediction revealed additional smaller CpG islands located 
apart from the NimbleGen-predicted CpG island.  However, this observed discrepancy 
does not necessarily extend to all genes identified as differentially methylated using the 
NimbleGen platform, as additional random inspection showed good alignment (data not 
shown).  The Bmp1 gene promoter genomic DNA was clearly hypermethylated in sham 
lung tissues, as a large region spanning about 2400 bp of methylation had peak scores 
above the 2.0 threshold (Fig. 16). This methylation pattern was consistent for all 
individuals in the sham group and was also very similar to the methylation pattern 
evident for normal adjacent lung tissues obtained from DBC- or BaP-initiated mice. 
Alternatively, methylation was largely absent in this region in tumor tissues obtained 
from DBC- or BaP-exposed offspring, save for two small regions of hypermethylation in 
one animal in the TumBaP group (Fig. 16). Similarly, the gene promoter genomic DNA 
for Fgfr1op (Fig. 17) was methylated in all sham lung tissue and adjacent normal tissues 
obtained from DBC- or BaP-initiated mice. Yet no tumor tissue samples had methylation 
surpassing the threshold score (a −log10 p-value > 2). A related pattern was observed for 
the Hoxb1 promoter, for which all individuals in the sham group were similar to the 
methylation pattern evident for normal adjacent lung tissues (Fig. 18). Interestingly, 
within the tiled region of Hoxb1, there were two regions of methylation separated by  
 FIG. 16. Methylation of Bmp1 promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Bmp1 obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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 FIG. 17. Methylation of Fgfr1op promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Fgfr1op obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all 
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands 
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples 
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red, 
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is 
represented by two tracks, the peak scores and threshold score >2.0. The threshold score 
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have 
surpassed the significance threshold and are thus considered to be hypermethylated. The 
peak score track displays the resulting score for each probe calculated as -log10 p-value 
using the one-sided Kolmogorov-Smirnov test. 
 
 
 
66 
 FIG. 18. Methylation of Hoxb1 promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Hoxb1 obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all 
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands 
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples 
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red, 
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is 
represented by two tracks, the peak scores and threshold score >2.0. The threshold score 
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have 
surpassed the significance threshold and are thus considered to be hypermethylated. The 
peak score track displays the resulting score for each probe calculated as -log10 p-value 
using the one-sided Kolmogorov-Smirnov test. 
 
 
 
67 
 
 
 
68 
about 1,600 bps, for both the sham group and the adjacent normal tissues obtained from 
DBC-initiated mice. 
In contrast, the methylation pattern across sample types was entirely different for 
Bcl2l11, which was highly methylated in all tumor samples and had relatively no 
methylation of adjacent normal or sham samples (Fig. 19). The methylated regions for 
Bcl2l11 ranged from 500 bp to 1500 bp, and all but one BaP tumor sample were 
hypermethylated within the same 1700 bp span (location Chr2: 127949400-127951100). 
A similar pattern was observed for the Pdcd4 promoter, for which hypermethylation was 
evident for a short region (approximately 400 bp) in TumDBC tissue and a region of 
varying length (400 to 1200 bp) in TumBaP tissues (Fig 20). The Pdcd4 gene promoter 
was mostly not methylated in normal adjacent lung tissues and sham tissues. A related 
methylation pattern for Pten was observed, for which methylation peaks were evident 
within all the DBC-initiated tumor samples (Fig. 21). A major difference was observed in 
that methylation was largely absent from the BaP-exposed offspring. The Pten gene 
promoter was mostly not methylated in normal adjacent lung tissues and sham tissues.  
For both Casp7 (Fig 22) and IL11 (Fig 23) gene promoters, the methylation 
pattern was consistent for all the sham tissue samples with methylation peak scores above 
the 2.0 threshold for regions of about 200 to 600bp in length. While some methylation 
was apparent in other tissue types, none of the peak score values for those samples 
exceeded the threshold indicating hypermethylation. 
 FIG. 19. Methylation of Bcl2l11 promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Bcl2l11 obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all 
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands 
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples 
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red, 
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is 
represented by two tracks, the peak scores and threshold score >2.0. The threshold score 
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have 
surpassed the significance threshold and are thus considered to be hypermethylated. The 
peak score track displays the resulting score for each probe calculated as -log10 p-value 
using the one-sided Kolmogorov-Smirnov test. 
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 FIG. 20. Methylation of Pdcd4 promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Pdcd4 obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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 FIG. 21. Methylation of Pten promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Pten obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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 FIG. 22. Methylation of Casp7 promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Casp7 obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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 FIG. 23. Methylation of Il11 promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Il11 obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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The promoter methylation pattern for the oncogene Maea was consistent in sham 
lung tissues across all individuals, as peak scores exceeded the 2.0 threshold for a region 
of approximately 1,000 bp (Fig 24). Smaller regions (200 to 400 bp) of hypermethylation 
were observed in one adjacent normal DBC sample, two adjacent normal BaP samples 
and one BaP tumor sample. All the methylated regions across all samples types for Maea 
range fell within the same 1,200 bp span (location Chr5: 33675200-33676400). Similarly, 
the Tpd52l1 gene promoter genomic DNA was methylated in all sham lung tissues, one 
normal adjacent BaP sample and two BaP tumor samples (Fig 25). Alternatively, 
methylation was mostly absent from the adjacent normal and DBC lung tumor tissue 
samples. In addition, all the methylated peaks of Tpd52l1’s promoter were in the same 
area within the tiled region (location Chr10: 31166600-31167900).  
Methylation patterns obtained from the Nimblgen genome-wide array were 
compared to profiles obtained by 454 amplicon sequencing for Cdkn2a, Dapk1, Mgmt 
and Rarb. According to the methylation profile obtained by the array, the Cdkn2a gene 
promoter was hypermethylated in one of three sham normal lung samples, two of three 
tumor samples and one of three in the normal adjacent tissues for both carcinogen 
initiated groups (Fig. 26). The gene promoter DNA for Dapk1 was methylated across 
nearly all sample types, with methylated regions varying in length from 100 bp to 1300 
bp (Fig. 27). In contrast, the methylation pattern was markedly different for both Mgmt 
and Rarb.  Some methylation was noted for the Mgmt promoter in two of the three sham 
normal tissues, but no significant methylation in any tissues from PAH-initiated animals 
(Fig. 28). Conversely, the Rarb gene promoter was devoid of any methylation in all 
 
 
 
FIG. 24. Methylation of Maea promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Maea obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands (black) and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Tracks representing control samples are shown in 
grey, adjacent normal DBC samples as blue, tumor DBC samples as red, adjacent normal 
BaP as green and tracks for tumor BaP as orange. Each sample is represented by two 
tracks, the peak scores and threshold score >2.0. The threshold score >2.0 track 
visualizes, by means of the solid bar, the region of peak scores that have surpassed the 
significance threshold and are thus considered to be hypermethylated. The peak score 
track displays the resulting score for each probe calculated as -log10 p-value using the 
one-sided Kolmogorov-Smirnov test. 
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FIG. 25. Methylation of Tpd52l1 promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Tpd52l1 obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all 
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands 
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples 
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red, 
adjacent normal BaP as green and tracks for tumor BaP as orange. Each sample is 
represented by two tracks, the peak scores and threshold score >2.0. The threshold score 
>2.0 track visualizes, by means of the solid bar, the region of peak scores that have 
surpassed the significance threshold and are thus considered to be hypermethylated. The 
peak score track displays the resulting score for each probe calculated as -log10 p-value 
using the one-sided Kolmogorov-Smirnov test. 
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FIG. 26. Methylation of Cdkn2a promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Cdkn2a obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands (black) and tiled regions are all 
mapped according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands 
predicted by EMBOSS Cpgplot are shown in purple. Tracks representing control samples 
are shown in grey, adjacent normal DBC samples as blue, tumor DBC samples as red, 
adjacent normal BaP as green and tracks for tumor BaP as orange. Bright pink indicates 
the region of this gene analyzed by bisulfite amplicon sequencing by 454 (data shown in 
Fig. 8). Each sample is represented by two tracks, the peak scores and threshold score 
>2.0. The threshold score >2.0 track visualizes, by means of the solid bar, the region of 
peak scores that have surpassed the significance threshold and are thus considered to be 
hypermethylated. The peak score track displays the resulting score for each probe 
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test. 
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FIG. 27. Methylation of Dapk1 promoter in normal and tumor lung tissues. This 
figure illustrates methylation profiles for the promoter region of Dapk1 obtained using 
the NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter 
Array. Chromosomal location, predicted CpG islands and tiled regions are all mapped 
according to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by 
EMBOSS Cpgplot are shown in purple. Bright pink indicates the region of this gene 
analyzed by bisulfite amplicon sequencing by 454 (data shown in Fig. 9). Tracks 
representing control samples are shown in grey, adjacent normal DBC samples as blue, 
tumor DBC samples as red, adjacent normal BaP as green and tracks for tumor BaP as 
orange. Each sample is represented by two tracks, the peak scores and threshold score 
>2.0. The threshold score >2.0 track visualizes, by means of the solid bar, the region of 
peak scores that have surpassed the significance threshold and are thus considered to be 
hypermethylated. The peak score track displays the resulting score for each probe 
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test. 
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 FIG. 28. Methylation of Mgmt promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Mgmt obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands and tiled regions are all mapped according 
to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by EMBOSS 
Cpgplot are shown in purple. Bright pink indicates the region of this gene analyzed by 
bisulfite amplicon sequencing by 454 (data shown in Fig. 10). Tracks representing 
control samples are shown in grey, adjacent normal DBC samples as blue, tumor DBC 
samples as red, adjacent normal BaP as green and tracks for tumor BaP as orange. Each 
sample is represented by two tracks, the peak scores and threshold score >2.0. The 
threshold score >2.0 track visualizes, by means of the solid bar, the region of peak scores 
that have surpassed the significance threshold and are thus considered to be 
hypermethylated. The peak score track displays the resulting score for each probe 
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test. 
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sample types (Fig. 29). Unfortunately, none of the regions for which differential 
methylation was observed using the genome-wide array aligned with the region analyzed 
by 454 sequencing, even though CpG islands were targeted for the ultra-deep sequencing 
analysis
 
 
 
FIG. 29. Methylation of Rarb promoter in normal and tumor lung tissues. This figure 
illustrates methylation profiles for the promoter region of Rarb obtained using the 
NimbleGen Mouse DNA Methylation 3×720K CpG Island Plus RefSeq Promoter Array. 
Chromosomal location, predicted CpG islands and tiled regions are all mapped according 
to the NCBI37/mm9 mouse genome assembly. Also, CpG islands predicted by EMBOSS 
Cpgplot are shown in purple. Bright pink indicates the region of this gene analyzed by 
bisulfite amplicon sequencing by 454 (data shown in Fig. 11). Tracks representing 
control samples are shown in grey, adjacent normal DBC samples as blue, tumor DBC 
samples as red, adjacent normal BaP as green and tracks for tumor BaP as orange. Each 
sample is represented by two tracks, the peak scores and threshold score >2.0. The 
threshold score >2.0 track visualizes, by means of the solid bar, the region of peak scores 
that have surpassed the significance threshold and are thus considered to be 
hypermethylated. The peak score track displays the resulting score for each probe 
calculated as -log10 p-value using the one-sided Kolmogorov-Smirnov test. 
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DISCUSSION 
 
This study is the first to profile genome-wide DNA promoter methylation in lung 
tissues of mice exposed to environmental PAH carcinogens. Two different methodologies 
were employed in the investigation of promoter methylation in normal and tumor lung 
tissues from offspring exposed in utero to the environmental carcinogens DBC or BaP. 
Targeted gene promoter amplicon analysis revealed consistent low methylation within the 
regions sequenced for all four target genes. The genome-wide assessment of CpG island 
promoter methylation revealed distinct patterns of methylation associated with normal 
and adenocarcinoma lung tissues. Gene ontology analysis revealed differences in the 
biological functions represented by the methylated genes in normal lung tissues 
compared to tumor tissues, such as cell proliferation, cell differentiation, cell cycle and 
growth, all of which are associated with the regulation and control of critical processes 
involved in lung tumorigenesis. These observations contribute to the growing knowledge 
that gene promoter methylation is a highly coordinated epigenetic event that is critical for 
the initiation and progression of lung cancer (Belinsky, 2015). 
 The genome-wide assessment of DNA methylation in the present model 
identified a methylation signature for lung tumorigenesis in PAH-exposed mice. A 
methylation profile was evident that distinguished normal lung tissue from tumor tissue 
obtained from mice initiated with either PAH carcinogen. Moreover, distinctions in DNA 
methylation were also evident when contrasting methylation profiles for tumors obtained 
from DBC- or BaP-initiated offspring. These distinctions were observed at the level of 
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specific genes as well as in the higher order analysis of enriched GO pathways. Venn 
diagram analysis identified cohorts of genes uniquely methylated in tumor tissues from 
DBC-initiated (125 genes) or BaP-initiated (142 genes), as well as those genes that 
shared a pattern of hypermethylation (92 genes). The enriched GO pathways represented 
by gene lists from lung tumor tissue obtained from DBC- or BaP-exposed offspring 
(Table 9) demonstrate the differences in methylation for these exposures. Altogether, 
these data provide new knowledge that exposure to specific PAHs, though similar in 
ultimate phenotypic effect, can lead to unique epigenetic profiles in lung tumors in adult 
offspring. 
The utilization of the two methodologies employed in the present study, genome-
wide and targeted amplicon methylation analysis, can lead to further functional or 
biological analyses of the disease state. Bisulfite amplicon sequencing provides a rich 
data set with CpG site-specific resolution for a small targeted region, approximately 300 
bp. Thus, researchers must have prior knowledge or reasonable expectation that the gene 
targets will be differentially methylated in the assayed tissue. One may rely on evidence 
from the literature to select target genes for amplicon analyses, as in the case for this 
study. Alternatively, this prior knowledge may be gained from other methylation analysis 
methods, such as a genome-wide methylation array, which yields a massive amount of 
data useful for discovering new target genes of interest. The genome-wide methylation 
array may also reveal patterns of methylation between groups and provide information 
for use in higher order gene ontology pathway analysis. However, the use of microarrays 
as a first-line approach has limitations, notably with respect to their high cost, which 
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necessitates limited experiment design. Furthermore, array analyses do not provide CpG 
site-specific data, rather a relative score indicative of methylation for a region of about 50 
bp. When these two approaches are used in conjunction, researchers may be able to better 
understand the significance of the methylation profiles and their biological impact.  
Based on the results obtained from analysis of the genome-wide DNA 
methylation data, we identified ten genes of interest for more in-depth examination of 
their role in carcinogenesis and evidence for methylation in lung cancer or other cancers 
in human or animal models. These genes include Bcl2l11, Bmp1, Fgfr1op, Hoxb1, Pdcd4, 
Casp7, IL11, Pten, Maea, and Tpd52l1.  One should note that these genes are not 
necessarily representative of genome-wide methylation patterns for any particular tissue 
or disease state, and their selection was subjective in nature.  
Bcl-2-like protein 11 (Bcl2l11) belongs to the Bcl-2 protein family of pro-
apoptotic genes. In this study, the promoter region of Bcl2l11 was hypermethylated in 
lung tumors of BaP- and DBC-initiated adult offspring. Others have reported that BCL2 
was hypermethylated in human NSCLC with a methylation frequency of 42% (i.e., 42% 
of tumors assessed had detectable levels of methylation) (Chung, et al., 2011; Zhao et al., 
2013). However, no information on methylation of Bcl2l11 in lung cancer in humans or 
animal models was available prior to this research. Hypermethylation of Bcl2l11 has been 
shown for other types of cancer, such as adenoid cystic carcinoma (Bell et al., 2011), 
chronic myeloid leukemia with 44% methylation prevalence (San Jose-Eneriz et al., 
2009) and colon cancer with 68% promoter methylation (Cho et al., 2014). Bcl2l11 binds 
to anti-apoptotic proteins, which allow the proapoptotic multidomain proteins Bax and 
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Bak to form channels on the mitochondrial membrane leading to cytochrome c release 
and apoptosis (Willis et al., 2007). Rahmani et al. suggested that Bcl2l11 is associated 
with the disruption of kinase pathways in human leukemia cells leading to apoptotic 
signaling (Rahmani et al., 2009). Moreover, Bcl2l11 was shown to be critical for 
apoptosis during negative selection of autoreactive thymocytes (Bouillet et al., 2002), 
mature T cells (Davey et al., 2002) and B cells (Enders et al., 2003). Also, Bcl2l11 
expression controlled the proliferation rate of tumor cells (Akiyama et al., 2009). Several 
researchers have obtained evidence suggesting that EGFR-driven NSCLC maintained a 
survival advantage via targeting Bcl2l11 protein for proteasomal degradation through 
MAPK dependent phosphorylation (Costa et al., 2007; Cragg et al., 2007; Gong et al., 
2007). Promoter hypermethylation of Bcl2l11, as seen in the present study, may be 
advantageous for tumor cells as the proapoptotic function of Bcl2l11 is suppressed. 
Bone morphogenetic proteins (BMP) are secreted glycoproteins belonging to the 
transforming growth factor-β super family. The present study is the first to observe 
hypomethylation of the Bmp1 gene promoter tissues obtained from mouse lung 
adenocarcinoma in contrast with expansive regions of hypermethylation in normal 
adjacent and sham lung tissues. Other BMPs were hypomethylated in cancers, such as 
BMP6 in endometrial cancer (Hsu et al., 2013). Alternatively, BMP3b and BMP6 were 
silenced by methylation in NSCLC (Dai et al., 2001; Dai et al., 2004; Kraunz et al., 
2005). Components of the BMP signaling cascade include protein kinases and 
transcription factors belonging to the SMAD family which transduce the BMP signal to 
the nucleus. The BMP gene family has been associated with an extensive range of actions 
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in cancer (Bandyopadhyay et al., 2013; Hatakeyama et al., 1997). For example, 
activation of BMP signaling inhibits some cancer types, such as colorectal cancer, by 
promoting growth arrest and differentiation (Blanco Calvo et al., 2009). Additionally, 
abnormal BMP expression was reported in association with development and progression 
of cancer of the colon, stomach, prostate and lungs (Dai, et al., 2001; Dai, et al., 2004; 
Horvath et al., 2004; Kodach et al., 2008; Wen et al., 2006). Bone morphogenetic protein 
1 is known to induce cartilage and bone formation and is a contributor to cell 
differentiation. In this study, Bmp1 gene promoter regions exhibited a substantial loss of 
methylation in the lung tumor tissue samples in comparison to the clearly methylated 
normal adjacent and sham lung tissue samples. This methylation pattern is in accordance 
with a role for Bmp1 in contributing to PAH-induced tumorigenesis, possibly through 
induction of cell proliferation.  
A similar methylation pattern was observed for fibroblast growth factor receptor 1 
oncogene partner (Fgfr1op), for which the promoter region was hypermethylated in 
normal and normal adjacent tissues but not methylated in tumor tissues from DBC- or 
BaP-initiated mice. To our knowledge, this report is the first to examine methylation of 
Fgfr1op in lung cancer. Cortese et al. (2008) observed hypermethylation in lung cancer 
samples for other members of the FGFR family, such as Fgfr3, which was methylated in 
100% of sampled lung adenocarcinomas and 70% of squamous cell carcinomas. 
Moreover, Fgfr1 was associated with hypomethylation in Rhabdomyosarcoma tumors in 
all samples tested (Goldstein et al., 2007). Fgfr1op is a fusion partner of Fgfr1 (Popovici 
et al., 1999), and this chimeric protein induces myeloproliferative disease in both humans 
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and mice (Guasch et al., 2004; Vizmanos et al., 2004). Gene ontology annotations related 
to Fgfr1op include organelle organization, localization, protein localization and 
macromolecular localization. Over-expression of FGFR1OP may contribute to the 
malignancy of human lung cancer by reduced ABL1-dependant phosphorylation of 
WRNIP1, resulting in cell cycle progression of lung tumors (Mano et al., 2007). A pro-
survival effect of Fgfr1 has been observed in diverse cancer cells, including leukemia, 
melanoma and bladder cancer (Feng et al., 2015). In the present study, the pattern of gene 
promoter methylation observed fit with the presumed oncogenic function of Fgfr1op.  
Homeobox B1 (Hoxb1) belongs to the homeobox (HOX) family of genes. The 
methylation pattern found in this study for Hoxb1 revealed the promoter region was 
hypermethylated in normal sham and normal adjacent tissues, but not methylated in 
tumor tissues from DBC- or BaP-initiated mice. Interestingly, Hoxb1 was 
hypermethylated in downstream regions of the human A549 lung cancer cells, while 
several other HOX genes were hypermethylated in the promoter regions (Rauch et al., 
2007). Furthermore, promoter hypermethylation silenced Hoxb1 in acute myeloid 
leukemia cells, with the hypermethylated fraction of the CpG island being 68 – 97% 
higher in respect to normal cells (Petrini et al., 2013). In addition,  researchers showed 
Hoxb1 to have increased methylation levels in pituitary adenomas (Duong et al., 2012) 
and oral squamous cell carcinoma with a mean frequency of promoter hypermethylation 
of 98% (Xavier et al., 2014). HOX genes encode transcription factors that are defined by 
the DNA-binding domain known as homeodomain (Gehring et al., 1994). In addition to 
their roles in development and stem cell differentiation, HOX genes are frequently 
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deregulated in several different cancers including cancers of the colon, bladder, kidney, 
breast, prostate, thyroid, ovarian, melanoma and lung (Bhatlekar et al., 2014). Abate-
Shen defined three categories of homeobox gene expression in tumor malignancy (Abate-
Shen, 2002). In the first, homeobox genes that are normally only active during embryonic 
development are re-expressed in the neoplastic cells. This first category accounts for 
most cases of aberrant HOX gene expression (Abate-Shen, 2002). In the second category, 
homeobox genes can be expressed in malignant cells derived from tissue in which a 
particular gene is not expressed during embryogenesis. In the third category, homeobox 
genes can be down-regulated in malignant cells derived from tissues in which a particular 
gene is normally expressed in the fully differentiated state. When compared to Abate-
Shen’s three categories, the present study’s methylation pattern for Hoxb1 is most similar 
to the first category of homeobox gene expression. However, the pattern of aberrant 
expression of specific HOX genes tends to differ based on tissue type and tumor site, and 
consequently, more research is needed to elucidate the role Hoxb1 plays in lung cancer. 
The methylation profile observed from the present study of programmed cell 
death 4 (Pdcd4) gene promoter DNA was hypermethylated in the lung tumor samples 
compared to control. No other evidence for Pdcd4 methylation in lung cancer has been 
shown to date. However, 5’ CpG island methylation at the transcription start site of 
PDCD4 blocks expression at the mRNA level in human glioma cell lines (Gao et al., 
2009). PDCD4 was also hypermethylated in the gene promoter of 36% of human gastric 
cancer samples (Cao et al., 2012). Pdcd4 encodes a nuclear/cytoplasmic phosphoprotein 
which modulates the transcription of specific genes by affecting the activity of certain 
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transcription factors. Pdcd4, described as a tumor suppressor, promotes cell apoptosis, 
reduces tumorigenesis and inhibits cellular invasion (Lankat-Buttgereit and Goke, 2009). 
Thus, Pdcd4 down-regulation is an unfavorable prognosis in lung, colon, esophageal, 
ovarian and brain cancer (Chen et al., 2003; Fassan et al., 2010; Gao, et al., 2009; 
Mudduluru et al., 2007; Wei et al., 2009). Down regulation of Pdcd4 may contribute to 
tumor development in at least two ways. Decreased Pdcd4 expression increases mobility 
and invasiveness of tumor cells (Asangani et al., 2008; Leupold et al., 2007; Wang et al., 
2008) and deregulates the cell response to DNA damage (Bitomsky et al., 2008; Singh et 
al., 2009). Hypermethylation of a gene promoter region, such as Pdcd4 in the present 
study, is typically correlated with down regulation of tumor suppressor gene expression 
which may be a contributing factor in carcinogenesis, as discussed above.  
In this study, the Caspase-7 (Casp7) gene promoter was hypermethylated in only 
the normal lung tissue of sham animals. While limited data are available on the 
methylation profiles of caspase genes, Hopkins-Donaldson et al. showed that caspase-8 
was methylated in 52% of small cell lung cancers and none of the NSCLC samples 
(2003). Furthermore, Teitz et al. (2000) found that caspase-8 was highly methylated in 
neuroblastomas. Caspase-7 is an apoptosis-related cysteine peptidase and belongs to a 
family of cysteine proteases that participate in apoptotic and inflammatory signaling 
pathways (Fiandalo and Kyprianou, 2012).  Because of the comparable specificities of 
caspases, these proteins may have some functional redundancy in vitro (Luthi and Martin, 
2007). However, caspases have been shown to display distinct activities in vivo (Slee et 
al., 2001), which may be explained by a compensatory mechanism (Zheng et al., 2000). 
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Caspase-7, along with caspase-3, is responsible for the execution of the apoptosis 
program through cleavage of caspase-activated DNase (Larsen et al., 2010). Caspase-7 
and -3 are downstream targets for caspase-9, which becomes catalytically active 
following formation of the apoptosome (Ohtsuka et al., 2003). If caspase-9 is inactive, 
then the downstream executioner caspases’ activation is inhibited (Janssen et al., 2007). 
Additionally, caspase-8 is activated during apoptosis induction and cleaves caspase-7 and 
-3, leading towards apoptosis (Yuan and Kroemer, 2010). There is relatively little 
evidence to support a central role for a single caspase in tumorigenesis, rather, caspases 
may perform their functions jointly resulting in the combined effect of all caspases 
(Olsson and Zhivotovsky, 2011). The promoter methylation profile for Casp7 pointed to 
a loss of methylation in tumor tissues from PAH-initiated animals initiated samples, 
further research is needed to fully elucidate the role of Casp7 in lung tumorigenesis. 
In this study, the promoter region of interleukin 11 (Il11) was hypermethylated in 
normal lung tissue of sham-initiated adult offspring. While methylation of IL11 in lung 
cancer has not been investigated to date, researchers studying major depressive disorder 
reported that the average CpG site methylation frequency was low in blood samples, 
ranging from 1%-9% (Powell et al., 2013). Furthermore, other interleukins have been 
shown to be methylated in lung cancer, such as IL12RB2 with methylation evident in 
42% of primary NSCLCs (Suzuki et al., 2007). An interplay between genetic variants and 
DNA methylation of IL13 was shown to influence asthma-related lung function (Patil et 
al., 2013). Il11 is a multifunctional cytokine that directly stimulates the proliferation of 
hematopoietic stem cells. Il11 plays a role in regulating cell proliferation, transcription, 
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cell-cell signaling, gene expression and establishment of localization. Il11 signaling has 
been associated with growth of osteosarcoma (Lewis et al., 2009) and is thought to 
facilitate cell motility in human chondrosarcoma cells (Li et al., 2012b). Multiple 
researchers established that Il11 plays a key role in the metastasis of breast cancer to 
bone (Ren et al., 2013; Ren et al., 2014; Sotiriou et al., 2001). Furthermore, Il11 has been 
shown to be an important factor mediating the proliferation and invasion of human 
colorectal cancer (Chua et al., 2013; Yamazumi et al., 2006). Along with previously 
mentioned cancers, Il11 expression is associated with cervical, pancreatic, prostate and 
liver cancers (Ernst and Putoczki, 2014). Thus, the low methylation observed for 
Il11gene promoter in the PAH-exposed offspring suggests an involvement in lung cancer 
development, possibly through induction of cell proliferation.  
In the present study, the promoter region of phosphatase and tensin homolog 
(Pten) gene was hypermethylated in the lung tissues obtained from mice initiated with 
DBC in utero. Differences observed between DBC- and BaP-initiated tissue samples may 
be reflective of the different potency of these PAH compounds, as DBC is a more potent 
mutagen with a higher rate of DNA adduct formation. Methylation of Pten has previously 
been identified in lung cancer with 35% prevalence in NSCLC samples and 69% 
prevalence among the NSCLC cell lines tested (Li et al., 2012a; Maeda et al., 2015; Soria 
et al., 2002). Additionally, hypermethylation of the Pten promoter region has been 
reported in numerous cancer types, such as breast cancer with a 48% methylation 
prevalence (Garcia et al., 2004), glioblastomas (Wiencke et al., 2007), gastric cancer with 
73% methylation prevalence (Kang et al., 2002) and endometrial cancer with 19% 
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methylation prevalence (Salvesen et al., 2001). Pten is an important tumor suppressor 
gene that acts through its phosphatase protein as a regulator of the cellular 
phosphoinositide 3-kinase signaling pathway. This pathway regulates a wide range of 
important biological processes. Thus, it is unsurprising that dysregulation of this 
signaling pathway plays a key role in several different disease states (Leslie and Downes, 
2004). Gene ontology annotations related to Pten include gene expression, cell 
communication, response to stimulus, cell differentiation and cell death, among several 
others. Pten is the most frequently mutated gene in prostate cancer, yet mutation of Pten 
is rarely observed in lung cancer (9%) (Chu and Tarnawski, 2004). Methylation is 
considered the main factor contributing to low expression of Pten in NSCLC cells (Soria, 
et al., 2002). 
This study was the first to determine a methylation profile for macrophage 
erythroblast attacher (Maea) in lung cancer, and to our knowledge, no other data are 
available describing the methylation status of Maea in other cancers. Maea, also known 
as EMP (erythroblast macrophage protein) or human lung cancer oncogene 10 protein, 
has been commonly associated with erythroblast/macrophage interactions during 
erythroid differentiation and enucleation of erythroblasts (Hanspal et al., 1998; Mohandas 
and Chasis, 2010; Soni et al., 2008). Moreover, Maea undergoes dynamic rearrangements 
that may be involved in cytokinesis and cell division (Bala et al., 2006). In addition, 
Maea is widely distributed in nonerythroid cells, such as heart, placenta, brain, liver, 
kidney, pancreas, skeletal muscle and lung (Hanspal, et al., 1998). Gene ontology 
annotations associated with Maea include cell cycle, regulation of biological quality 
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control, cell differentiation, cytoskeleton organization and organelle organization. The 
observed low methylation profile of PAH-exposed lung tissue samples for Maea, as seen 
in the present study, suggest that this gene may contribute to cancer development in 
DBC-initiated offspring.  
The present study is the first to observe a methylation profile for tumor protein 
D52-like 1 (Tpd52l1) in lung cancer. The promoter region of Tpd52l1 was consistently 
hypermethylated in lung tissue obtained from all sham-initiated offspring, 
hypomethylated in all tissues from DBC-initiated animals and intermittently methylated 
in BaP-initiated mice. Tpd52l1 is a member of the tumor protein D52 (Tpd52) family and 
is involved in cell proliferation and calcium signaling. Byrne et al. (1995) identified the 
first D52-like gene, after which the Tpd52 family was identified to be contributors in 
several human cancers including breast cancer (Boutros and Byrne, 2005), colon cancer 
(Malek et al., 2002), ovarian cancer (Byrne et al., 2005), prostate cancer (Wang et al., 
2004), glioma (Wang et al., 2014), melanoma (Roesch et al., 2007), and lung cancer 
(Chen et al., 1996).  Loss of methylation of the Tpd52l1 promoter, as observed in DBC-
exposed offspring, may promote growth of tumor cells as loss of methylation allows for 
Tpd52l1 to increase proliferation.  
The four target genes selected for gene promoter amplicon analysis were selected 
based on prior knowledge from the literature (see Table 1). Methylation analysis of four 
genes (Cdkn2a, Rarb, Dapk1 and Mgmt) using 454 deep bisulfite sequencing of CpG 
sites at single base pair resolution on targeted regions within the promoter CpG island 
revealed consistent low levels of methylation within all four genes. A conserved region of 
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hypermethylation in Cdkn2a amplicon was detected across all sample types, covering 
four CpG sites from bp -156 to -169 upstream in relation to the first bp of the first exon. 
Although interesting, the biological significance of the elevated methylation at this 
location has yet to be determined. Furthermore, the approach taken in the present study 
was an in-depth look at single base pair resolution within a targeted region of the 
promoter of these four genes. Putative CpG island sites of the promoter regions varied in 
length and number between the target genes. The CpG island within Cdkn2a was large, 
beginning -1,000 bp upstream of the first exon and extending to about 300 bp 
downstream. Rarb contained three separate CpG islands ranging from -300 bp to 100 bp 
in relation to the first bp of the first exon. A single large CpG island surrounded Dapk1 
first exon beginning at -180 bp extending to 750 bp past the first exon. Finally, the CpG 
island with the promoter region of Mgmt began at -225 bp and extended to 25 bp, in 
relation to the first bp of the first exon. Given the number of sample types to be examined 
and the depth of sequencing desired using 454 technology, the experiment design allowed 
for only one region to be sequenced per gene. Thus, it is possible that other regions of the 
gene promoter were differentially methylated. Indeed, since this analysis was performed, 
new cost-effective technologies have become available that would allow for more 
extensive methylation analysis of the entire promoter region, while also allowing for a 
large number of samples to be sequenced. Our approach aimed at CpG site-specific 
methylation in an attempt to achieve a greater depth of analysis, resulting in a fine 
resolution of data which can only be achieved by sequencing. In addition to the amplicon 
sequencing, the four target genes methylation profiles were identified using the genome-
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wide assessment of DNA methylation, which corresponded with the low levels of 
methylation observed for the sequenced regions. Interestingly, three of the four target 
gene promoter regions were methylated in regions not analyzed by bisulfite sequencing. 
However, the methylation patterns observed for these genes differed based on tissue type 
and, consequently, the pattern of gene promoter methylation observed did not fit with the 
presumed tumor suppressor function of these cancer critical genes.  
Results of this study provide further supporting evidence that DBC is a 
substantially more potent transplacental carcinogen when compared to BaP. Even though 
BaP was administered at a substantially higher dose than DBC, lung tumor incidence was 
only a fraction (29.5%) of the rate observed for DBC-initiated offspring (100%). A 
similar trend was also observed for lung tumor multiplicity. Initial studies of 
transplacental exposure to DBC and BaP using the cross of strain B6129SF1/J dams to 
129S1/SvlmJ sires were developed by Yu et al. (2006a; 2006b). The incidence of lung 
tumors in initial studies employing a single high dose was 100% and the average lung 
tumor multiplicity was 13 to 15 per tumor-bearing animal (Castro, et al., 2008a; Castro, 
et al., 2008b; Castro et al., 2009; Castro, et al., 2008c; Yu, et al., 2006a; Yu, et al., 
2006b). In a subsequent study, Shorey et al. (2012) developed a multiple dosing regimen 
resulting in reduced gross lung tumor incidence of 80% and reduced multiplicity (3 
tumors per tumor-bearing animal) in comparison to previous studies. Our gross lung 
tumor data, utilizing the multiple dosing regimen, more closely resembled the outcome of 
the initial single high dose studies, with 100% tumor incidence and tumor multiplicity 
typically ranging from 3 to 15 tumors per tumor-bearing animal within the DBC group. 
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BaP previously had never been used in a multiple dosing regimen, and lung tumor 
incidence was 30% with lung tumor multiplicity at one to two tumors per tumor-bearing 
animal. Although the study was not designed to compare lung tumorigenesis among 
males and females, we did make an interesting observation that lung tumor incidence was 
lower in BaP-initiated females than in males. Historically, lung cancer incidence is 
consistently higher in men compared to women in all populations, with sex ratios varying 
from about 1.5 to 20 (International Agency for Research on Cancer, 2008). Tobacco 
smoke is a major risk factor for lung cancer, and gender differences in lung cancer 
mortality reflect patterns of smoking uptake and cessation over time (American Cancer 
Society, 2015). However, other researchers found that women may be more susceptible 
to tobacco smoke and potentially more vulnerable to lung cancer (Kiyohara and Ohno, 
2010). Further work is needed to understand the gender differences in susceptibility to 
lung cancer.  
In conclusion, we identified a set of cancer-related genes with distinct methylation 
profiles according to tissue type using a genome-wide approach to assess DNA promoter 
methylation tumor tissues of offspring initiated with DBC or BaP in utero in comparison 
to normal lung tissue from sham-initiated offspring. These new genes of interest may be 
important targets for epigenetic modification during the process of lung tumorigenesis in 
animals exposed to environmental PAHs. However, it remains to be seen whether PAH 
exposure directly results in their altered methylation or their methylation state is 
indicative of the cancer disease state. To address this uncertainty, these newly identified 
target genes may be subject to 454 sequencing analysis in the same manner as the four 
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tumor suppressor genes originally selected for this study. Another future application of 
the data from this work would be a comparison of the methylation profile obtained for 
PAH-initiated lung tumors in mice to methylation profile for human NSCLC. Such an 
analysis may provide insight into the applicability of this transplacental carcinogenesis 
animal model as a model for human lung cancer with respect to epigenome modifications 
that occur during lung carcinogenesis. In future bioinformatics analyses, we plan to 
address these questions by comparing the methylation profile obtained in the present 
study with those publicly available for human NSCLC. A greater understanding of the 
epigenetic events that contribute to lung tumorigenesis may enhance approaches for lung 
cancer prevention and treatment and may reduce the heavy burden of this devastating 
disease.  
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Appendix A 
 
 
NimbleGen Processed Data Report for All Methylated Peaks.   
The complete data set for all detected peaks on the NimbleGen mouse 
methylation array is provided as a digital data set accessible at the DOI link in the 
following reference (Fish, 2015a).  The .zip archive includes 15 individual digital 
Microsoft Excel documents, one for each sample hybridized to the NimbleGen mouse 
methylation array. Names of the individual Excel documents are provided in Table A.1, 
and these documents were named according to the sample type (Sham, AdjDBC, 
TumDBC, AdjBaP and TumBaP) and replicate (A, B and C).  Table A.2 provides a 
description of the file content according to the spreadsheet column title.  
 
TABLE A.1 
List of File Names Included in the Archive File for Appendix A 
Sham_A_553635A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
Sham_B_553565A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
Sham_C_553574A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjDBC_A_553634A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjDBC_B_553654A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjDBC_C_553635A02_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumDBC_A_553634A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumDBC_B_553565A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumDBC_C_553653A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjBaP_A_553653A02_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjBaP_B_553653A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
AdjBaP_C_553565A02_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumBaP_A_553635A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumBaP_B_553574A03_ratio_peaks_mapToFeatures_All_Peaks.xls 
TumBaP_C_554845A01_ratio_peaks_mapToFeatures_All_Peaks.xls 
 
FIG. 1. Worldwide lung cancer incidence and mortality. (A) Estimated number of 
cases for the most common cancers worldwide in 2012. (B) Bars represent the 
estimated number of new lung cancer cases and the estimated number of lung 
cancer deaths as a percentage of all cancers (excluding non-melanoma skin 
cancers) for male or females in developed (dark blue) or developing (light blue) 
nations. Numbers above the bar represent the number of cases or deaths. (C) World 
map depicting incidence of lung cancer by nation for both males and females 
(values shown are the age-standardized rate per 100,000 people). Source data were 
obtained from the GLOBOCAN 2012 database (Ferlay et al., 2013). 
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TABLE A.2 
Definitions of File Contents for Appendix A by Spreadsheet Column Title 
Column Description 
PEAK_ID An ID for each mapped peak 
CHROMOSOME Chromosome associated with peak 
PEAK_START First base of the peak on the chromosome 
PEAK_END Last base of the peak on the chromosome 
PEAK_SCORE Average −log10 p-value for probes in the peak region 
FEATURE_TRACK The annotation track against which peaks were mapped, 
which is the transcription start site for this data set 
FEATURE_STRAND Strand of the transcript 
FEATURE_START First base of the feature on the chromosome 
Note: For the transcription start site, feature size is 1; 
therefore, start and end positions are the same.  
FEATURE_END Last base of the feature on the chromosome 
FEATURE_TO_PEAK_
DISTANCE 
Distance from center of peak to the feature 
Parent Internal identification number of the transcript from which the 
transcript start site is generated 
Accession NCBI RefSeq Accession ID 
Name Gene symbol of the transcript 
Description Full gene name of the transcript 
Ncbi_gene_id NCBI Entrez GeneID of the transcript 
Synonyms Other alias symbol(s) of the transcript 
attr1 (etc.) Other available attributes for the transcript 
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Appendix B 
 
NimbleGen Processed Data Report for Nearest Methylated Peaks.   
The complete data set for peaks nearest to the transcription start site on the 
NimbleGen mouse methylation array is provided as a digital data set accessible at the 
DOI link in the following reference (Fish, 2015b). The .zip archive includes 15 individual 
digital Microsoft Excel documents, one for each sample hybridized to the NimbleGen 
mouse methylation array. Names of the individual Excel documents are provided in 
Table B.1, and these documents were named according to the sample type (Sham, 
AdjDBC, TumDBC, AdjBaP and TumBaP) and replicate (A, B and C).  Table B.2 
provides a description of the file content according to the spreadsheet column title.  
 
TABLE B.1 
List of File Names Included in the Archive File for Appendix B 
Sham_A_553635A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
Sham_B_553565A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
Sham_C_553574A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjDBC_A_553634A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjDBC_B_553654A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjDBC_C_553635A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumDBC_A_553634A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumDBC_B_553565A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumDBC_C_553653A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjBaP_A_553653A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjBaP_B_553653A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
AdjBaP_C_553565A02_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumBaP_A_553635A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumBaP_B_553574A03_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
TumBaP_C_554845A01_ratio_peaks_mapToFeatures_Nearest_Peak.xls 
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TABLE B.2  
Definitions of File Contents for Appendix B by Spreadsheet Column Title 
Column Description 
PEAK_ID An ID for each mapped peak 
CHROMOSOME Chromosome associated with peak 
PEAK_START First base of the peak on the chromosome 
PEAK_END Last base of the peak on the chromosome 
PEAK_SCORE Average −log10 p-value for probes in the peak region 
FEATURE_TRACK The annotation track against which peaks were mapped, which 
is the transcription start site for this data set 
FEATURE_STRAND Strand of the transcript 
FEATURE_START First base of the feature on the chromosome 
Note: For the transcription start site, feature size is 1; therefore, 
start and end positions are the same.  
FEATURE_END Last base of the feature on the chromosome 
FEATURE_TO_PEAK
_DISTANCE 
Distance from center of peak to the feature 
Parent Internal identification number of the transcript from which the 
transcript start site is generated 
Accession NCBI RefSeq Accession ID 
Name Gene symbol of the transcript 
Description Full gene name of the transcript 
Ncbi_gene_id NCBI Entrez GeneID of the transcript 
Synonyms Other alias symbol(s) of the transcript 
attr1 (etc.) Other available attributes for the transcript 
 
 
  
141 
 
 
Appendix C 
 
 
Peak Scores Summary Table for All Methylated Genes in Any Data Set.   
A summary table of peak scores for the nearest peak to the indicated transcript for 
any peak significantly methylated (score ≥ 2.0) in any of the 15 samples analyzed are 
provided as a Microsoft Excel file available at a DOI link in the following reference 
(Fish, 2015c). Table C.1 provides a description of the file content according to the 
spreadsheet column title. 
 
TABLE C.1 
Definitions of File Contents for Appendix C by Spreadsheet Column Title 
Column Description 
MGI Gene Mouse Genome Informatics (MGI) Accession number 
NCBI gene ID NCBI Entrez GeneID of the transcript 
Symbol Gene symbol of the transcript 
Name Full gene name of the transcript 
Peak Score Average −log10 p-value for probes in the peak region 
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Appendix D 
 
 
Gene Lists for Ontology Analyses 
 
Table D.1 indicates the specific comparisons performed to generate gene lists for 
ontology analysis and the number of genes in each resulting data set.  These lists are 
provided as a Microsoft Excel file available at the DOI link included in the following 
reference (Fish, 2015d).  Within this spreadsheet, each column contains a set of gene 
accession numbers (MGI accession) representing genes methylated in one (or more) 
tissue type(s) and not in others according to the comparisons outlined in Table D.1.  
 
 
TABLE D.1 
List of Comparisons Among Tissue Types to Generate  
Gene Lists for Ontology Analyses 
Comparisons  Number of genes in list 
Methylated in Sham but not AdjDBC or TumDBC 271 
Methylated in AdjDBC but not Sham or TumDBC 147 
Methylated in TumDBC but not Sham or AdjDBC 150 
Methylated in Sham but not AdjBAP or TumBAP 160 
Methylated in AdjBAP but not Sham or TumBAP 159 
Methylated in TumBAP but not Sham or AdjBAP 218 
Methylated in Sham but not TumDBC or TumBAP 239 
Methylated in TumDBC but not Sham or TumBAP 127 
Methylated in TumBAP but not Sham or TumDBC 143 
Methylated in TumDBC and TumBAP but not Sham 93 
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Results of Gene Ontology Analyses for Differentially Methylated Genes 
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 TABLE E.1.  
AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, AdjDBC and TumDBC Tissues 
      
Methylated in  
Sham tissues 
Methylated in  
AdjDBC tissue 
Methylated in  
TumDBC tissue 
Ontology GO Term Description FDR  Num  FDR  Num  FDR  Num  
P GO:0048856 anatomical structure development   5.00E-04 39   
  
  1.50E-03 25 
P GO:0009653 anatomical structure morphogenesis   2.10E-03 24   
  
  3.20E-02 13 
P GO:0065007 biological regulation   1.70E-03 80   
  
  3.10E-03 48 
P GO:0009058 biosynthetic process   5.60E-03 49   
  
  2.10E-03 33 
P GO:0005975 carbohydrate metabolic process   2.80E-02 10   
  
  
  P GO:0007154 cell communication   
  
  
  
  2.10E-02 13 
P GO:0007049 cell cycle   1.50E-02 14   
  
  
  P GO:0030154 cell differentiation   1.50E-02 26   
  
  7.40E-03 18 
P GO:0008283 cell proliferation   3.90E-02 14   
  
  8.90E-03 11 
P GO:0044249 cellular biosynthetic process   3.80E-03 49   
  
  1.60E-03 33 
P GO:0016043 cellular component organization   5.80E-03 32   
  
  1.70E-03 23 
P GO:0048869 cellular developmental process   1.50E-02 27   
  
  1.10E-02 18 
P GO:0034645 cellular macromolecule biosynthetic process   1.80E-02 35   
  
  1.20E-02 23 
P GO:0044260 cellular macromolecule metabolic process   8.80E-05 63   
  
  2.50E-03 36 
P GO:0044237 cellular metabolic process   5.40E-06 82   2.10E-02 42   2.90E-06 54 
P GO:0009987 cellular process   1.10E-06 131   2.10E-02 66   4.70E-09 87 
P GO:0044267 cellular protein metabolic process   1.30E-02 28   
  
  
  P GO:0032502 developmental process   1.20E-04 47   
  
  2.70E-03 27 
P GO:0051234 establishment of localization   
  
  
  
  2.70E-03 24 
P GO:0010467 gene expression   5.60E-03 40   
  
  4.20E-03 26 
P GO:0040007 growth   
  
  
  
  3.50E-02 7 
P GO:0006629 lipid metabolic process   
  
  
  
  1.00E-03 13 
P GO:0051179 localization   6.20E-03 39   
  
  2.30E-03 27 
P GO:0009059 macromolecule biosynthetic process   1.90E-02 35   
  
  1.20E-02 23 
P GO:0043170 macromolecule metabolic process   4.90E-06 73   
  
  2.50E-03 39 
P GO:0043412 macromolecule modification   5.00E-04 26   
  
  
  P GO:0008152 metabolic process   2.30E-07 98   7.80E-03 49   2.70E-05 57 
P GO:0007275 multicellular organismal development   4.00E-05 46   
  
  2.40E-03 26 
P GO:0032501 multicellular organismal process   6.20E-03 57   2.80E-03 40   1.50E-02 34 
P GO:0006807 nitrogen compound metabolic process   3.60E-03 46   
  
  2.50E-02 26 
P GO:0006139 
nucleobase, nucleoside, nucleotide and nucleic acid 
metabolic process   6.70E-03 41   
  
  8.60E-03 26 
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Methylated in  
Sham tissues 
Methylated in  
AdjDBC tissue 
Methylated in  
TumDBC tissue 
Ontology GO Term Description FDR  Num  FDR  Num  FDR  Num  
P GO:0006996 organelle organization   1.80E-02 19   
  
  
  P GO:0044238 primary metabolic process   1.80E-06 85   
  
  4.50E-05 51 
P GO:0019538 protein metabolic process   2.70E-03 36   
  
  
  P GO:0006464 protein modification process   6.60E-04 25   
  
  
  P GO:0050789 regulation of biological process   9.40E-03 69   
  
  3.10E-02 40 
P GO:0065008 regulation of biological quality   5.60E-03 29   
  
  2.70E-03 20 
P GO:0050794 regulation of cellular process   2.00E-02 64   
  
  3.50E-02 38 
P GO:0010468 regulation of gene expression   5.00E-04 36   
  
  
  P GO:0060255 regulation of macromolecule metabolic process   2.00E-03 37   
  
  8.90E-03 22 
P GO:0019222 regulation of metabolic process   5.60E-03 38   
  
  1.50E-03 27 
P GO:0000003 reproduction   5.80E-03 14   
  
  1.40E-02 9 
P GO:0006350 transcription   5.80E-03 30   
  
  
  P GO:0006810 transport   4.90E-02 31   
  
  2.70E-03 24 
F GO:0005488 binding   1.50E-17 152   1.20E-03 66   4.70E-09 83 
F GO:0003824 catalytic activity   4.30E-08 76   7.60E-03 36   2.20E-05 45 
F GO:0043169 cation binding   4.30E-08 58   
  
  4.00E-02 24 
F GO:0043167 ion binding   4.30E-08 58   
  
  2.70E-02 25 
F GO:0046872 metal ion binding   4.30E-08 58   
  
  3.90E-02 24 
F GO:0005515 protein binding   1.30E-05 73   8.40E-04 42   6.90E-03 40 
F GO:0003677 DNA binding   1.00E-04 32   
  
  
  F GO:0005509 calcium ion binding   1.00E-04 15   
  
  
  F GO:0016787 hydrolase activity   1.70E-04 36   
  
  8.10E-03 21 
F GO:0003676 nucleic acid binding   1.90E-03 37   
  
  2.00E-02 22 
F GO:0000166 nucleotide binding   5.00E-03 31   
  
  6.90E-03 21 
F GO:0016773 phosphotransferase activity, alcohol group as acceptor   1.00E-02 14   
  
  
  F GO:0016301 kinase activity   4.10E-02 14   
  
  
  C GO:0044464 cell part   8.70E-21 190   1.50E-08 98   3.20E-13 108 
C GO:0005623 cell   8.70E-21 190   1.50E-08 98   3.20E-13 108 
C GO:0005622 intracellular   2.90E-15 141   
  
  3.10E-08 77 
C GO:0044424 intracellular part   5.30E-15 138   
  
  3.50E-08 75 
C GO:0043229 intracellular organelle   8.00E-12 117   
  
  3.10E-08 68 
C GO:0043226 organelle   8.30E-12 117   
  
  3.10E-08 68 
C GO:0043231 intracellular membrane-bounded organelle   9.60E-11 105   
  
  3.10E-08 63 
C GO:0043227 membrane-bounded organelle   9.60E-11 105   
  
  3.10E-08 63 
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Methylated in  
Sham tissues 
Methylated in  
AdjDBC tissue 
Methylated in  
TumDBC tissue 
Ontology GO Term Description FDR  Num  FDR  Num  FDR  Num  
C GO:0005737 cytoplasm   8.40E-10 98   
  
  6.30E-05 52 
C GO:0044444 cytoplasmic part   5.60E-08 67   
  
  5.70E-04 35 
C GO:0016020 membrane   5.00E-05 90   5.20E-08 64   4.40E-06 59 
C GO:0005634 nucleus   5.80E-05 59   
  
  3.50E-04 36 
C GO:0042995 cell projection   4.90E-04 19   
  
  
  C GO:0005654 nucleoplasm   1.60E-03 12   
  
  
  C GO:0005783 endoplasmic reticulum   1.90E-03 18   
  
  
  C GO:0031974 membrane-enclosed lumen   4.30E-03 15   
  
  
  C GO:0070013 intracellular organelle lumen   7.20E-03 14   
  
  
  C GO:0043233 organelle lumen   7.20E-03 14   
  
  
  C GO:0044446 intracellular organelle part   7.70E-03 36   
  
  7.70E-03 23 
C GO:0044422 organelle part   8.80E-03 36   
  
  8.40E-03 23 
C GO:0005576 extracellular region   1.10E-02 25   2.20E-02 17   9.60E-04 19 
C GO:0031981 nuclear lumen   1.10E-02 12   
  
  
  C GO:0005773 vacuole   1.50E-02 7   
  
  
  C GO:0005886 plasma membrane   1.60E-02 37   
  
  1.90E-02 23 
C GO:0043234 protein complex   2.80E-02 27   
  
  
  C GO:0044428 nuclear part   4.20E-02 15   
  
  
  P GO:0033036 macromolecule localization   3.40E-02 16   
  
  
  P GO:0008104 protein localization   4.10E-02 14   
  
  
  F GO:0004871 signal transducer activity   
  
  8.40E-04 27   
  F GO:0004872 receptor activity   
  
  8.40E-04 26   
  F GO:0060089 molecular transducer activity   
  
  8.40E-04 27   
  F GO:0005102 receptor binding   
  
  1.40E-02 10   
  P GO:0006091 generation of precursor metabolites and energy   4.10E-02 7   
  
  
  P GO:0007010 cytoskeleton organization   4.90E-02 8   
  
  
  P GO:0008219 cell death   
  
  6.40E-03 14   
  P GO:0016265 death   
  
  6.40E-03 14   
  F GO:0003723 RNA binding   
  
  
  
  8.50E-03 10 
F GO:0005215 transporter activity   
  
  
  
  2.30E-02 12 
F GO:0016740 transferase activity   
  
  
  
  2.50E-02 16 
F GO:0015075 ion transmembrane transporter activity   
  
  
  
  2.50E-02 9 
F GO:0030234 enzyme regulator activity   
  
  
  
  2.70E-02 9 
F GO:0022857 transmembrane transporter activity   
  
  
  
  2.70E-02 10 
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Methylated in  
Sham tissues 
Methylated in  
AdjDBC tissue 
Methylated in  
TumDBC tissue 
Ontology GO Term Description FDR  Num  FDR  Num  FDR  Num  
F GO:0022892 substrate-specific transporter activity   
  
  
  
  3.10E-02 10 
F GO:0022891 substrate-specific transmembrane transporter activity   
  
  
  
  3.80E-02 9 
F GO:0022803 passive transmembrane transporter activity   
  
  
  
  4.00E-02 6 
F GO:0015267 channel activity   
  
  
  
  4.00E-02 6 
C GO:0005794 Golgi apparatus   
  
  
  
  2.70E-03 11 
C GO:0005739 mitochondrion   
  
  
  
  2.70E-03 16 
C GO:0044421 extracellular region part   
  
  
  
  9.40E-03 11 
C GO:0005578 proteinaceous extracellular matrix   
  
  
  
  9.80E-03 6 
C GO:0031012 extracellular matrix   
  
  
  
  1.50E-02 6 
C GO:0031967 organelle envelope   
  
  
  
  4.10E-02 7 
C GO:0031975 envelope   
  
  
  
  4.30E-02 7 
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples of interest 
and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the methylated Sham list were 
consistently methylated in only the sham tissues. Gene ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse 
gene ontology database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under dependency correction and significance level of P<0.05 and 
the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a generic GO slim (Gene Ontology Consortium). GO terms shown above are for 
biological processes (B), molecular function (F) and cellular component (C). For each tissue, the FDR-adjusted P value and the number of genes associated with the GO term 
are shown. Color blocks indicate the level of significance for each GO term, color-coded according to the tissue type for cross reference with figures and supplemental materials 
(gray scale, Sham; blue scale, AdjDBC; red scale, TumDBC). Absence of P value and gene numbers for a GO term indicates that that term was not significantly enriched for 
that particular gene set. For clarity, in cases where a biological process is represented in more than one tissue type, the specific methylated genes associated with that term are 
different for each tissue. 
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 TABLE E.2.  
 AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, AdjBaP and TumBaP Tissues 
      
Methylated in Sham 
tissues 
Methylated in 
AdjBaP tissue 
Methylated in 
TumBaP tissue 
Ontology GO Term Description   FDR  Num    FDR  Num    FDR  Num  
P GO:0048856 anatomical structure development   7.50E-03 26   
  
  2.60E-06 40 
P GO:0009653 anatomical structure morphogenesis   5.10E-05 22   
  
  5.00E-05 25 
P GO:0065007 biological regulation   
  
  
  
  2.40E-04 70 
P GO:0009058 biosynthetic process   
  
  5.50E-04 36   5.30E-05 49 
P GO:0005975 carbohydrate metabolic process   
  
  2.10E-02 8   2.30E-02 9 
P GO:0007154 cell communication   
  
  
  
  2.40E-04 22 
P GO:0030154 cell differentiation   
  
  3.80E-02 17   2.20E-03 25 
P GO:0008283 cell proliferation   3.90E-02 12   
  
  2.00E-02 13 
P GO:0007267 cell-cell signaling   
  
  
  
  1.10E-02 10 
P GO:0006519 cellular amino acid and derivative metabolic process   
  
  2.80E-03 8   
  P GO:0044249 cellular biosynthetic process   
  
  3.60E-04 36   8.40E-05 47 
P GO:0048869 cellular developmental process   
  
  
  
  4.00E-03 25 
P GO:0034645 cellular macromolecule biosynthetic process   
  
  2.10E-02 24   6.20E-04 35 
P GO:0044260 cellular macromolecule metabolic process   
  
  
  
  6.20E-04 50 
P GO:0044237 cellular metabolic process   
  
  3.10E-05 53   8.40E-05 65 
P GO:0009987 cellular process   
  
  4.90E-05 79   1.00E-09 119 
P GO:0044267 cellular protein metabolic process   
  
  
  
  1.30E-02 24 
P GO:0032502 developmental process   3.90E-02 27   
  
  6.00E-05 41 
P GO:0051234 establishment of localization   
  
  2.00E-02 23   8.40E-05 36 
P GO:0045184 establishment of protein localization   
  
  2.50E-02 10   
  P GO:0042592 homeostatic process   
  
  
  
  2.20E-02 12 
P GO:0006629 lipid metabolic process   
  
  3.30E-04 14   2.30E-02 12 
P GO:0051179 localization   
  
  3.70E-02 24   4.90E-05 41 
P GO:0009059 macromolecule biosynthetic process   
  
  2.10E-02 24   1.50E-04 37 
P GO:0033036 macromolecule localization   
  
  2.50E-02 12   
  P GO:0043170 macromolecule metabolic process   
  
  
  
  5.10E-05 59 
P GO:0008152 metabolic process   3.90E-02 50   3.10E-05 59   4.60E-07 82 
P GO:0007275 multicellular organismal development   3.90E-02 25   
  
  5.50E-05 39 
P GO:0032501 multicellular organismal process   
  
  2.30E-04 43   2.30E-03 50 
P GO:0006807 nitrogen compound metabolic process   
  
  8.20E-03 30   1.70E-02 36 
P GO:0044238 primary metabolic process   
  
  2.40E-05 55   1.10E-05 70 
P GO:0019538 protein metabolic process   
  
  
  
  3.70E-03 30 
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Methylated in Sham 
tissues 
Methylated in 
AdjBaP tissue 
Methylated in 
TumBaP tissue 
Ontology GO Term Description   FDR  Num    FDR  Num    FDR  Num  
P GO:0050789 regulation of biological process   
  
  
  
  1.20E-03 62 
P GO:0065008 regulation of biological quality   
  
  
  
  1.70E-02 23 
P GO:0050794 regulation of cellular process   
  
  
  
  2.90E-03 58 
P GO:0060255 regulation of macromolecule metabolic process   
  
  
  
  9.10E-03 29 
P GO:0019222 regulation of metabolic process   
  
  
  
  6.60E-03 32 
P GO:0050896 response to stimulus   
  
  4.00E-02 22   
  P GO:0006412 translation   
  
  
  
  8.00E-03 10 
P GO:0006810 transport   
  
  2.00E-02 23   8.40E-05 36 
F GO:0005488 binding   3.30E-05 78   4.60E-06 78   1.70E-10 115 
F GO:0043169 cation binding   3.00E-03 30   1.10E-03 30   
  F GO:0043167 ion binding   3.00E-03 30   1.10E-03 30   
  F GO:0046872 metal ion binding   3.00E-03 30   1.10E-03 30   
  F GO:0003677 DNA binding   4.00E-02 17   
  
  
  F GO:0016788 hydrolase activity, acting on ester bonds   5.00E-02 9   
  
  
  F GO:0003824 catalytic activity   
  
  2.70E-06 49   2.20E-04 56 
F GO:0060089 molecular transducer activity   
  
  1.60E-04 30   
  F GO:0004871 signal transducer activity   
  
  1.60E-04 30   
  F GO:0004872 receptor activity   
  
  2.10E-04 28   
  F GO:0016787 hydrolase activity   
  
  5.00E-04 24   
  F GO:0008289 lipid binding   
  
  3.70E-02 6   
  F GO:0005515 protein binding   
  
  
  
  4.30E-05 62 
F GO:0005215 transporter activity   
  
  
  
  2.60E-03 18 
C GO:0044464 cell part   2.80E-09 107   5.80E-11 108   7.00E-27 170 
C GO:0005623 cell   2.80E-09 107   5.80E-11 108   7.00E-27 170 
C GO:0005622 intracellular   5.60E-05 73   1.60E-04 70   3.20E-17 124 
C GO:0044424 intracellular part   5.60E-05 72   1.60E-04 69   1.20E-15 119 
C GO:0043229 intracellular organelle   4.10E-04 61   2.50E-03 57   6.70E-10 95 
C GO:0043226 organelle   4.10E-04 61   2.50E-03 57   6.70E-10 95 
C GO:0005576 extracellular region   1.50E-03 20   
  
  1.00E-02 22 
C GO:0016020 membrane   3.00E-03 54   2.10E-09 70   1.60E-12 96 
C GO:0043231 intracellular membrane-bounded organelle   1.20E-02 50   3.60E-03 51   4.40E-07 80 
C GO:0043227 membrane-bounded organelle   1.20E-02 50   3.60E-03 51   4.40E-07 80 
C GO:0005737 cytoplasm   2.60E-02 46   3.30E-03 49   8.30E-14 93 
C GO:0044444 cytoplasmic part   4.00E-02 31   1.60E-03 36   6.70E-10 62 
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Methylated in Sham 
tissues 
Methylated in 
AdjBaP tissue 
Methylated in 
TumBaP tissue 
Ontology GO Term Description   FDR  Num    FDR  Num    FDR  Num  
C GO:0005886 plasma membrane   
  
  7.10E-03 26   2.90E-08 47 
C GO:0005794 Golgi apparatus   
  
  2.00E-02 10   
  C GO:0005768 endosome   
  
  2.80E-02 6   
  C GO:0005773 vacuole   
  
  3.50E-02 5   
  C GO:0005829 cytosol   
  
  
  
  6.00E-04 13 
C GO:0005739 mitochondrion   
  
  
  
  1.40E-02 19 
C GO:0044422 organelle part   
  
  
  
  1.60E-02 30 
C GO:0016023 cytoplasmic membrane-bounded vesicle   
  
  
  
  2.30E-02 8 
C GO:0044446 intracellular organelle part   
  
  
  
  2.40E-02 29 
C GO:0031988 membrane-bounded vesicle   
  
  
  
  3.10E-02 8 
C GO:0005634 nucleus   
  
  
  
  3.70E-02 40 
C GO:0043232 intracellular non-membrane-bounded organelle   
  
  
  
  3.80E-02 21 
C GO:0043228 non-membrane-bounded organelle   
  
  
  
  3.80E-02 21 
Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples 
of interest and excluding all features that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the 
methylated Sham list were consistently methylated in only the sham tissues. Gene ontology was performed using AgriGO (Du, et al., 2010) using the singular 
enrichment analysis tool against the mouse gene ontology database (Mouse Genome Informatics) with the following parameters: Fisher test with FDR under 
dependency correction and significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a 
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes (B), molecular function (F) and cellular component (C). For 
each tissue, the FDR-adjusted P value and the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO 
term, color-coded according to the tissue type for cross reference with Figures and supplemental materials (gray scale, Sham; green scale, AdjBAP; orange scale, 
TumBAP). Absence of P value and gene numbers for a GO term indicates that that term was not significantly enriched for that particular gene set. For clarity, in 
cases where a biological process is represented in more than one tissue type, the specific methylated genes associated with that term are different for each tissue. 
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 TABLE E.3.  
 AgriGO GO Slim Results for Biological Process, Molecular Function and Cellular Compartment for Sham, TumDBC and TumBaP Tissues 
      
Methylated in Sham 
tissues 
Methylated in 
TumDBC tissue 
Methylated in 
TumBaP tissue 
Methylated in 
TumDBC+TumBaP 
tissues 
Ontology GO Term Description   FDR Num 
 
FDR Num 
 
FDR Num 
 
FDR Num 
P   GO:0048856   anatomical structure development   2.10E-05 40   
  
  1.20E-02 22   1.30E-03 19 
P   GO:0009653   anatomical structure morphogenesis   1.20E-05 28   
  
  3.60E-03 16   6.80E-03 11 
P   GO:0065007   biological regulation   1.90E-03 72   
  
  3.70E-02 43   
  P   GO:0009058   biosynthetic process   7.10E-03 44   
  
  
  
  1.40E-03 24 
P   GO:0007154   cell communication   
  
  
  
  5.60E-03 15   
  P   GO:0030154   cell differentiation   3.60E-03 26   
  
  2.00E-02 17   
  P   GO:0008283   cell proliferation   1.80E-02 14   
  
  
  
  
  P   GO:0044249   cellular biosynthetic process   4.70E-03 44   
  
  
  
  1.30E-03 24 
P   GO:0016043   cellular component organization   1.10E-03 32   
  
  
  
  
  P   GO:0048869   cellular developmental process   1.90E-03 28   
  
  2.90E-02 17   
  P   GO:0034645   cellular macromolecule biosynthetic process   1.90E-03 36   
  
  
  
  1.40E-03 19 
P   GO:0044260   cellular macromolecule metabolic process   3.90E-04 55   
  
  
  
  2.70E-03 25 
P   GO:0044237   cellular metabolic process   2.10E-04 69   4.90E-04 42   2.00E-02 40   1.30E-03 32 
P   GO:0009987   cellular process   4.70E-08 124   5.20E-05 67   1.40E-05 77   1.30E-03 48 
P   GO:0044267   cellular protein metabolic process   3.50E-02 24   
  
  
  
  
  P   GO:0007010   cytoskeleton organization   3.00E-02 8   
  
  
  
  
  P   GO:0032502   developmental process   3.50E-05 45   
  
  2.20E-02 24   1.30E-03 21 
P   GO:0009790   embryonic development   3.50E-02 12   
  
  
  
  
  P   GO:0051234   establishment of localization   
  
  
  
  2.10E-03 25   
  P   GO:0010467   gene expression   1.30E-03 39   
  
  
  
  2.80E-03 19 
P   GO:0042592   homeostatic process   
  
  
  
  2.00E-02 10   
  P   GO:0051179   localization   8.70E-03 35   
  
  2.30E-03 27   
  P   GO:0009059   macromolecule biosynthetic process   2.10E-03 36   
  
  
  
  1.40E-03 19 
P   GO:0043170   macromolecule metabolic process   1.20E-05 66   
  
  2.30E-03 39   1.40E-03 28 
P   GO:0043412   macromolecule modification   2.20E-02 19   
  
  
  
  
  P   GO:0008152   metabolic process   2.70E-06 86   5.20E-05 50   7.10E-05 55   1.30E-03 37 
P   GO:0007275   multicellular organismal development   4.00E-05 42   
  
  2.00E-02 23   1.30E-03 20 
P   GO:0032501   multicellular organismal process   9.20E-04 56   
  
  4.80E-02 32   2.70E-02 23 
P   GO:0006807   nitrogen compound metabolic process   5.00E-03 41   
  
  
  
  6.40E-03 20 
P   GO:0006139   nucleobase, nucleoside, nucleotide and nucleic acid metabolic process   8.70E-03 37   
  
  
  
  5.20E-03 19 
P   GO:0006996   organelle organization   2.70E-03 20   
  
  
  
  
  P   GO:0044238   primary metabolic process   3.50E-05 73   1.50E-04 44   3.00E-04 48   1.40E-03 32 
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Methylated in Sham 
tissues 
Methylated in 
TumDBC tissue 
Methylated in 
TumBaP tissue 
Methylated in 
TumDBC+TumBaP 
tissues 
Ontology GO Term Description   FDR Num 
 
FDR Num 
 
FDR Num 
 
FDR Num 
P   GO:0019538   protein metabolic process   7.30E-03 31   
  
  2.00E-02 21   
  P   GO:0006464   protein modification process   3.00E-02 18   
  
  
  
  
  P   GO:0050789   regulation of biological process   5.10E-03 64   
  
  4.80E-02 39   
  P   GO:0050794   regulation of cellular process   2.30E-02 58   
  
  
  
  
  P   GO:0010468   regulation of gene expression   4.00E-05 36   
  
  
  
  2.50E-03 16 
P   GO:0060255   regulation of macromolecule metabolic process   2.10E-04 37   
  
  
  
  2.80E-03 17 
P   GO:0019222   regulation of metabolic process   8.10E-04 38   
  
  
  
  1.40E-03 19 
P   GO:0000003   reproduction   
  
  2.10E-02 9   
  
  
  P   GO:0006350   transcription   2.10E-03 29   
  
  
  
  1.40E-03 16 
P   GO:0006810   transport   
  
  
  
  2.10E-03 25   
  F   GO:0005488   binding   1.30E-12 129   2.30E-11 77   2.20E-07 77   7.10E-03 44 
F   GO:0003677   DNA binding   3.10E-05 32   
  
  
  
  1.20E-02 13 
F   GO:0046872   metal ion binding   1.00E-03 42   9.80E-04 26   4.90E-02 23   
  F   GO:0003824   catalytic activity   1.00E-03 57   1.50E-05 40   1.00E-04 42   
  F   GO:0043169   cation binding   1.00E-03 42   6.50E-04 27   3.70E-02 24   
  F   GO:0043167   ion binding   1.00E-03 42   3.10E-04 28   3.70E-02 24   
  F   GO:0005515   protein binding   1.00E-03 61   2.30E-02 32   4.90E-03 39   
  F   GO:0003676   nucleic acid binding   1.00E-03 35   
  
  
  
  7.10E-03 17 
F   GO:0005509   calcium ion binding   7.70E-03 11   
  
  
  
  
  F   GO:0030528   transcription regulator activity   1.00E-02 18   
  
  
  
  7.10E-03 11 
F   GO:0016787   hydrolase activity   1.10E-02 28   2.00E-02 17   3.70E-02 18   
  F   GO:0003700   transcription factor activity   4.50E-02 12   
  
  
  
  
  F   GO:0000166   nucleotide binding   
  
  9.80E-04 20   
  
  
  F   GO:0016740   transferase activity   
  
  4.00E-03 16   3.70E-02 15   
  F   GO:0030234   enzyme regulator activity   
  
  2.80E-02 8   3.70E-02 9   
  F   GO:0008233   peptidase activity   
  
  
  
  1.30E-03 11   
  F   GO:0016772   transferase activity, transferring phosphorus-containing groups   
  
  
  
  4.60E-02 10   
  F   GO:0016301   kinase activity   
  
  
  
  4.90E-02 9   
  F   GO:0005215   transporter activity   
  
  
  
  
  
  2.10E-02 9 
C   GO:0044464   cell part   9.00E-18 168   5.80E-10 89   9.90E-18 112   8.90E-09 68 
C   GO:0005623   cell   9.00E-18 168   5.80E-10 89   9.90E-18 112   8.90E-09 68 
C   GO:0044424   intracellular part   3.10E-11 118   1.10E-04 58   9.60E-10 77   2.30E-07 51 
C   GO:0005622   intracellular   3.10E-11 120   1.10E-04 59   3.90E-12 83   2.20E-07 52 
C   GO:0043226   organelle   4.60E-08 98   7.00E-04 49   2.40E-05 59   5.10E-08 48 
C   GO:0043229   intracellular organelle   7.30E-08 97   7.00E-04 49   2.40E-05 59   5.10E-08 48 
C   GO:0043231   intracellular membrane-bounded organelle   7.50E-06 83   3.70E-04 46   1.30E-04 52   2.30E-07 43 
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Methylated in Sham 
tissues 
Methylated in 
TumDBC tissue 
Methylated in 
TumBaP tissue 
Methylated in 
TumDBC+TumBaP 
tissues 
Ontology GO Term Description   FDR Num 
 
FDR Num 
 
FDR Num 
 
FDR Num 
C   GO:0043227   membrane-bounded organelle   7.50E-06 83   3.70E-04 46   1.30E-04 52   2.30E-07 43 
C   GO:0005737   cytoplasm   7.60E-06 79   1.30E-03 42   4.10E-09 61   7.40E-03 31 
C   GO:0005576   extracellular region   1.10E-05 31   3.20E-03 16   
  
  
  C   GO:0005634   nucleus   3.00E-05 55   1.50E-02 27   
  
  7.90E-05 27 
C   GO:0044446   intracellular organelle part   1.20E-03 36   4.70E-02 18   
  
  
  C   GO:0044422   organelle part   1.40E-03 36   4.90E-02 18   
  
  
  C   GO:0016020   membrane   1.50E-03 76   1.10E-04 49   2.10E-07 61   1.80E-02 32 
C   GO:0043232   intracellular non-membrane-bounded organelle   1.70E-03 27   
  
  
  
  
  C   GO:0043228   non-membrane-bounded organelle   1.70E-03 27   
  
  
  
  
  C   GO:0005615   extracellular space   3.10E-03 13   
  
  
  
  
  C   GO:0044444   cytoplasmic part   6.90E-03 46   1.30E-02 27   2.40E-05 38   1.80E-02 21 
C   GO:0005694   chromosome   7.00E-03 10   
  
  
  
  
  C   GO:0044421   extracellular region part   9.60E-03 15   
  
  
  
  
  C   GO:0032991   macromolecular complex   1.30E-02 31   
  
  
  
  
  C   GO:0005856   cytoskeleton   4.60E-02 16   
  
  
  
  
  C   GO:0005886   plasma membrane   
  
  2.90E-02 20   6.10E-04 27   
  C   GO:0005794   Golgi apparatus   
  
  3.50E-02 8   
  
  
  C   GO:0016023   cytoplasmic membrane-bounded vesicle   
  
  
  
  1.50E-03 8   
  C   GO:0031988   membrane-bounded vesicle   
  
  
  
  2.20E-03 8   
  C   GO:0031410   cytoplasmic vesicle   
  
  
  
  3.50E-03 9   
  C   GO:0005829   cytosol   
  
  
  
  3.60E-03 9   
  C   GO:0031982   vesicle   
  
  
  
  5.20E-03 9   
  Note: Gene lists for functional ontology analysis were generated by selecting features with Log2 peak ratio > 2 (indicates methylated DNA) in all three samples of interest and excluding all features 
that were not methylated (log2 peak ratio <2) in at least 2 of the 3 biological samples not of interest. Thus, genes in the methylated Sham list were consistently methylated in only the sham tissues. Gene 
ontology was performed using AgriGO (Du, et al., 2010) using the singular enrichment analysis tool against the mouse gene ontology database (Mouse Genome Informatics) with the following 
parameters: Fisher test with FDR under dependency correction and significance level of P<0.05 and the minimum number of mapping entries set at 5 genes. The gene ontology type performed was a 
generic GO slim (Gene Ontology Consortium). GO terms shown above are for biological processes (B), molecular function (F) and cellular component (C). For each tissue, the FDR-adjusted P value 
and the number of genes associated with the GO term are shown. Color blocks indicate the level of significance for each GO term, color-coded according to the tissue type for cross reference with 
Figures and supplemental materials (gray scale, Sham; red scale, TumDBC; orange scale, TumBaP; light blue scale, union set for both TumDBC and TumBaP). Absence of P value and gene numbers 
for a GO term indicates that that term was not significantly enriched for that particular gene set. For clarity, in cases where a biological process is represented in more than one tissue type, the specific 
methylated genes associated with that term are different for each tissue. 
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Appendix F 
 
 
Gene Ontology Maps 
 
Gene ontology maps were generated for all group comparisons outlined in Table 
D.1.; these maps are provided as high resolution .tif files at the DOI link available in the 
following reference (Fish, 2015e). This archive includes 10 individual image files (see 
Table F.1), each of which depicts a Gene Ontolgoy map for GO terms representing 
hypermethylated gene promoters unique for the indicated tissue(s) (listed first in file 
name) compared to other tissues.  Gene ontology analysis was performed using the 
AgriGO singular enrichment analysis (SEA) tool (http://bioinfo.cau.edu.cn/agriGO) 
against the mouse gene ontology database (Mouse Genome Informatics). Significantly 
enriched GO terms (Generic GO Slim) were determined using the Fisher test with an 
FDR-corrected significance level of P<0.05 (Yekutieli multi-test adjustment method) and 
the minimum number of mapping entries set at 5 genes.  
 
TABLE F.1 
List of File Names Included in the Archive File for Appendix F 
Figure designation File name 
Fig. F.1 GO Slim Map for Methylated in Sham, Not AdjDBC or TumDBC.tif	
Fig. F.2 GO Slim Map for Methylated in AdjDBC, Not Sham or TumDBC.tif	
Fig. F.3 GO Slim Map for Methylated in TumDBC, Not Sham or AdjDBC.tif	
Fig. F.4 GO Slim Map for Methylated in Sham, Not AdjBaP or TumBaP.tif	
Fig. F.5 GO Slim Map for Methylated in AdjBaP, Not Sham or TumBaP.tif	
Fig. F.6 GO Slim Map for Methylated in TumBaP, Not Sham or AdjBaP.tif	
Fig. F.7 GO Slim Map for Methylated in Sham, Not TumDBC or TumBaP.tif	
Fig. F.8 GO Slim Map for Methylated in TumDBC, Not Sham or TumBaP.tif	
Fig. F.9 GO Slim Map for Methylated in TumBaP, Not Sham or TumDBC.tif	
Fig. F.10 GO Slim Map for Methylated in TumDBC and TumBaP, Not Sham.tif	
 
